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ABSTRACT 
The creation of novel enzyme activity is a great challenge to protein engineers, but nature 
has done so repeatedly throughout the process of natural selection.  I begin by outlining the 
multitude of distinct reactions catalyzed by a single enzyme class, cytochrome P450 
monooxygenases. I discuss the ability of cytochrome P450 to generate reactive 
intermediates capable of diverse reactivity, suggesting this enzyme can also be used to 
generate novel reactive intermediates in the form of metal-carbenoid and nitrenoid species.  
I then show that cytochrome P450 from Bacillus megaterium (P450BM3) and its isolated 
cofactor can catalyze metal-nitrenoid transfer in the form of intramolecular C–H bond 
amination.  Mutations to the protein sequence can enhance the reactivity and selectivity of 
this transformation significantly beyond that of the free cofactor. Next, I demonstrate an 
intermolecular nitrene transfer reaction catalyzed by P450BM3 in the form of sulfide 
imidation. Understanding that sulfur heteroatoms are strong nucleophiles, I show that 
increasing the sulfide nucleophilicity through substituents on the aryl sulfide ring can 
dramatically increase reaction productivity. To explore engineering nitrenoid transfer in 
P450BM3, active site mutagenesis is employed to tune the regioselectivity intramolecular C–
H amination catalysts.  The solution of the crystal structure of a highly selective variant 
demonstrates that hydrophobic residues in the active site strongly modulate reactivity and 
regioselectivity.  Finally, I use a similar strategy to develop P450-based catalysts for 
intermolecular olefin aziridination, demonstrating that active site mutagenesis can greatly 
enhance this nitrene transfer reaction.  The resulting variant can catalyze intermolecular 
aziridination with more than 1000 total turnovers and enantioselectivity of up to 99% ee.
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CYP  Cytochrome P450 monooxygenase identifier 
P450  Cysteine-ligated cytochrome P450 monooxygenase    
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BM3  Cytochrome P450 from Bacillus megaterium (CYP102A1) 
CO  Carbon monoxide 
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KPi  Potassium monophosphate 
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C h a p t e r  1  
EXPANDING CYTOCHROME P450 REACTION SPACE THROUGH EVOLUTION 
AND ENGINEERING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as J. A. McIntosh, C. C. Farwell, F. H. Arnold “Expanding 
Cytochrome P450 Reaction Space Through Evolution and Engineering” in Current 
Opinion in Chemical Biology 2014, 19, 126-134. U. Bornscheuer, J. C. Moore, eds.  
J.A.M., F.H.A., and myself wrote the paper, where I contributed to the first, second, and 
fourth sections and also created all figures.  
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Abstract 
Advances in protein and metabolic engineering have led to the broad use of enzymes to 
synthesize important molecules.  However, many desirable transformations are not 
catalyzed by any known enzyme, driving interest in understanding how new enzymes can 
be created. The cytochrome P450 enzyme family, whose members participate in xenobiotic 
metabolism and natural products biosynthesis, catalyzes an impressive range of difficult 
chemical reactions that continues to grow as new enzymes are characterized.  Recent work 
has revealed that P450-derived enzymes can also catalyze useful reactions previously 
accessible only through synthetic chemistry.  The evolution and engineering of these 
enzymes provides an excellent case study for how to genetically encode new chemistry and 
expand biology’s reaction space.  
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Introduction 
 Impressive demonstrations of the use of engineered microbes to produce fuels and 
chemicals in recent years have led some to predict a future in which microbes can produce 
nearly all of the organic molecules upon which society depends from renewable resources.1  
This future may be desirable from the standpoint of energy efficiency and environmental 
sustainability, but it is also a ways off.  Successful metabolic engineering efforts have, for 
the most part, depended on reassembling natural enzymes into biosynthetic pathways.  
Many desired products unfortunately fall outside the reach of the rather limited set of 
known enzyme-catalyzed transformations.  Eventually, progress in biological production 
will depend on our ability to genetically encode new catalysts for known and novel 
chemical reactions.  
 Generating new enzymes de novo is difficult, although progress is being made with 
some relatively simple transformations—for example, computationally designed enzymes 
that catalyze the Kemp elimination and Diels-Alder reactions have been reported.2  Nature, 
it seems, agrees with this assessment, preferring to repurpose existing enzyme scaffolds 
rather than create whole new enzymes.3  Some scaffolds appear to be used more frequently 
than others: for example, the enolase and crotonase superfamilies (and many others) 
support several different reactions,4 whereas the dihydrofolate reductase family is only 
known to carry out a single reaction.5  Thus a biomimetic alternative to de novo protein 
design might exploit enzymes that nature has already used for chemical innovations.  But 
can nature’s past successes with catalytic diversification guide future efforts to generate 
new enzyme catalysts?  Recent work suggests that the versatility of cytochrome P450 
enzymes—which catalyze a multitude of reactions in nature—can indeed be replicated and 
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even expanded upon by enzyme engineers to genetically encode new biosynthetic 
capabilities.  
 Cytochrome P450 enzymes are most commonly associated with the hydroxylation 
and dealkylation of xenobiotic molecules in mammals, and in this case the substrate scope 
is vast.  But their natural roles far exceed this one niche.  Biosynthetic pathways to many 
natural products, such as terpenes (including steroids), alkaloids, and polyketides, involve 
P450-mediated oxidations, which add functional groups to simpler hydrophobic skeletons.  
P450s also occur in primary catabolic pathways for degradation of alkanes and other 
recalcitrant molecules.  Beyond their large substrate scope, many different reaction types 
have been characterized for naturally occurring and engineered P450s,6 including 
hydroxylation, epoxidation, sulfoxidation, aryl-aryl coupling, nitration, oxidative and 
reductive dehalogenations, and recently several synthetically important non-natural 
reactions (vide infra).  Given future challenges in synthetic biology, the ability of P450 
enzymes to assume new catalytic functions in natural and artificial contexts merits close 
inspection for insights into how we might discover or create new biocatalysts.  
In this review, we present examples of the broad catalytic range of P450 enzymes 
from papers published during the last two years, with an emphasis on newly characterized 
reactions, both naturally occurring and artificially conceived. To help distinguish between 
the many natural P450 reactions and newly discovered non-natural reactions, we first 
review key aspects of P450 catalysis and describe how these characteristics allow access to 
a diverse set of reactions.  Next, we describe recently published non-natural P450 reactions 
and contrast features of natural and non-natural chemical reactivity.  Finally, we discuss the 
broader relevance of P450 reaction diversity to the goal of engineering new enzymes. 
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Cytochrome P450: a platform for C–H activation 
Here we introduce the P450 catalytic cycle and the key reactive intermediates that 
are responsible for much of the natural reactivity of P450 enzymes.  Additionally, we make 
note of some of the key conserved residues involved in oxygen activation; mutations to 
some of these key residues lead to increased activity in non-natural reactions, as we 
describe below. For a more detailed treatment of the P450 mechanism, we refer the reader 
to more specialized reviews.6a,7   
In the resting state of the enzyme, the catalytic iron is in the ferric (+3) oxidation 
state (intermediate A in Figure 1).  P450s produce intermediates that are sufficiently 
reactive to attack even inert hydrocarbons.  Consequently, P450 enzymes have evolved 
mechanisms that prevent initiation of the catalytic cycle in the absence of substrate.  
Substrate binding initiates the catalytic cycle by increasing the redox potential of the heme 
prosthetic group, which makes it possible for an associated reductase to reduce the heme to 
the ferrous (+2) state.  The catalytic cycle continues with binding of molecular oxygen to 
the iron center to give a ferric superoxide complex (intermediate B in Figure 1).  A second 
electron transfer generates an iron-peroxo intermediate (C1 in Figure 1), which is then 
protonated to give an iron-hydroperoxy intermediate (C2 in Figure 1).  Subsequent 
protonation effects heterolytic cleavage of the O–O bond to form the high-valent iron-oxo 
intermediate known as compound I (intermediate D in Figure 1).  In hydroxylation 
reactions, compound I abstracts a hydrogen atom from a substrate C–H bond (formally a 
proton-coupled 1-electron oxidation of the substrate), yielding compound II and a substrate 
radical. These two radical species then rapidly recombine to produce the hydroxylated 
product and the ferric resting state of the enzyme. 
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Figure 1.  The P450 catalytic cycle.  The active site structure of P450BM3 is shown at center 
with conserved threonine (T268) and axial cysteine (C400) highlighted.  Key intermediates 
include the ferric resting state (A), the ferric superoxide intermediate (B), the iron-peroxo 
or hydroperoxy intermediates (C1, C2), and compound I (D).  
  
Although many interactions between the protein, its reductase partner, and the heme 
prosthetic group contribute to the smooth operation of the catalytic cycle, a few key 
residues merit special mention.  One is a conserved active-site threonine (T268 in Figure 
1), which, through water, helps to protonate the iron-peroxo and iron-hydroperoxy 
intermediates, thus promoting O–O bond scission to generate compound I.  Another key 
residue universally conserved among P450 enzymes is the axial cysteine that ligates the 
heme iron.  Thiolate ligation is thought to serve several functions.  For one, the electron-
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rich thiolate ligand makes the ferric heme a worse electron acceptor.  This decrease in 
redox potential helps to prevent triggering of the catalytic cycle in the absence of substrate.  
Another key role of the axial cysteine is to promote heterolytic O–O bond scission of the 
iron-hydroperoxy intermediate.  Finally, as Green has argued, thiolate ligation may bias 
compound I toward hydrogen abstraction chemistry.7c  In particular, the electron donating 
ability of the thiolate ligand makes compound I worse at performing 1-electron oxidations, 
but makes the 1-electron reduced form (known as compound II) much more basic, thus 
favoring proton-coupled 1-electron oxidations (i.e., hydrogen abstractions).   
 
Intermediates in the P450 catalytic cycle drive diverse natural chemical reactivity 
The expansive catalytic scope of P450 enzymes is obvious from even a partial 
listing of known P450-catalyzed reactions: aryl-aryl coupling, ring contractions and 
expansions, S- N- and O-dealkylations, decarboxylation, oxidative cyclization, alcohol and 
aldehyde oxidation, desaturation, sulfoxidation, nitrogen oxidation, epoxidation, C–C  bond 
scission, decarbonylation, and nitration.  Many of these transformations (heteroatom 
demethylations, decarboxylation, alcohol and aldehyde oxidation, desaturation, and others) 
are mechanistically very similar to hydroxylation (Figure 1) and result from the ability of 
compound I to perform hydrogen atom abstractions; others involve compound I-mediated 
oxidations distinct from hydrogen atom abstraction.  P450 enzymes, however, do not rely 
exclusively on compound I, as other intermediates in the catalytic cycle are responsible for 
some P450 transformations (Figure 2).  For example, the iron-peroxo (or hydroperoxide) 
intermediate can mediate epoxidation and sulfoxidation under some circumstances;8 in 
others this species carries out C–C  bond cleavage, as described below.   Likewise, the 
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initial oxygen adduct with ferrous heme (the ferric-superoxide intermediate, Figure 2, 
blue) is proposed to play a key role in P450-catalyzed nitration.9  P450 catalytic 
diversification in nature is thus enabled by the generation of multiple potentially reactive 
species during the P450 catalytic cycle, as well as the potency of P450-derived oxidants, 
which can react with substrates in different ways.  Though many potential oxidants occur 
during the cycle, natural P450s are often quite specific in the reactions that they catalyze.  
Specificity is directed by protein sequences molded by the force and filter of natural 
selection to favor certain intermediates while tuning their reactivity and selectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Key catalytic intermediates in the P450 cycle and examples of chemical 
reactions that rely on them.  In blue are highlighted the ferric superoxide intermediate and 
the nitration reaction that is associated with this intermediate. 9  In pink are highlighted the 
iron-peroxo and iron-hydroperoxy intermediates and C–C bond scission19 and 
sulfoxidation14 reactions.  Highlighted in green are compound I and desaturation,13 ring 
closure,10 sequential oxidation,12b and aryl coupling reactions.16 
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Beginning with compound I-derived oxidations, one particularly interesting P450-
mediated reaction occurs during biosynthesis of the natural product aureothin (Figure 2, 
green).  The P450 enzyme AurH first catalyzes hydroxylation of the aureothin precursor, 
followed by intramolecular C–O bond formation, to give a tetrahydrofuran ring, with both 
reactions presumably occurring with the intermediacy of compound I.10 Hertweck and 
coworkers have exploited this unusual enzyme to accomplish a biomimetic total synthesis 
of aureothin, as well as the synthesis of several aureothin derivatives;11 one example11c 
describes an active site mutation that converts AurH into a six-electron oxidase, leading to 
the conversion of a substrate methyl group all the way to a carboxylic acid. 
Several natural examples of sequential hydroxylations to yield ketones or 
carboxylates from unactivated C–H bonds have been described recently.12  For example, in 
xiamycin biosynthesis, the P450 enzyme XiaM was shown to catalyze sequential 
hydroxylation of a methyl group to a carboxylate.12a  Another example of multiple P450-
catalyzed oxidations was published by Höfer et al. in their investigation of the first steps of 
the biosynthesis of bioactive alkaloids vinblastine and secologanin (Figure 2, green).12b 
Though more typical of di-iron monooxygenases and α-ketoglutarate-dependent 
dioxygenases, desaturation has been observed with a few P450 enzymes.6b  An interesting 
example of P450-catalyzed desaturation was recently reported by Bell et al.13  CYP199A4 
was previously found to catalyze demethylation of several aromatic compounds, including 
4-methoxybenzoic acid and veratric acid, as well as hydroxylation (major product) and 
desaturation (minor product) of 4-ethylbenzoic acid.  In their recent report, these authors 
found two active site mutations (F185V and F185I) that markedly increase desaturation of 
  
10 
4-ethylbenzoic acid to yield 4-vinylbenzoic acid, with the isoleucine variant giving 
exclusively the desaturation product (Figure 2, green).  
Several examples of P450-catalyzed decarboxylation are associated with 
biosynthesis and drug metabolism.  One biotechnologically interesting P450-catalyzed 
decarboxylation leads to the synthesis of terminal alkenes from fatty acids.14  The authors 
propose a mechanism in which compound I abstracts the β-hydrogen, followed by 1-
electron oxidation of the resulting radical to yield a β-carbocation, which spontaneously 
decarboxylates to give the product.  
The above compound I-mediated transformations most likely proceed via hydrogen 
atom abstraction.  Another mechanism by which compound I can mediate oxidation is 
through sequential 1-electron oxidations.  Vancomycin and related antibiotics contain aryl 
C–C and C–O crosslinks catalyzed by P450-mediated 1-electron oxidations (Figure 2, 
green).  Recent work on the biosynthesis of these antibiotics includes the solution of two 
crystal structures of P450s involved in aryl coupling reactions,15 as well as a study that 
examines the timing of P450-catalyzed crosslinking during vancomycin biosynthesis.16 
Biochemical evidence suggests that the iron-peroxo intermediate can behave as an 
alternative oxidant in epoxidation and sulfoxidation reactions,8 though until recently17 
theoretical studies cast doubt on its role in sulfoxidation.18  It is generally accepted that the 
iron-peroxo species is the active oxidant in C–C  cleavage reactions.19 For example, recent 
work by Kincaid and coworkers supports the role of a substrate-influenced selectivity 
switch that promotes the stability of the iron-peroxo species, favoring C–C  lyase chemistry 
for certain steroid derivatives (Figure 2, pink).19  
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One of the most interesting P450 reactions characterized recently is that of 
tryptophan nitration in thaxtomin biosynthesis (Figure 2, blue).9  Here, neither compound I 
nor the iron-peroxo intermediate is thought to play the key role.  Instead, the initial adduct 
between ferrous heme and dioxygen, the ferric superoxide intermediate (Figure 1, B), is 
proposed to react with in situ generated nitric oxide to form ferric peroxynitrite.  The 
peroxynitrite species can then decompose via one of two pathways (neither of which has 
been directly supported so far).  In pathway (1), peroxynitrite decomposes homolytically to 
yield NO2 and an iron-ferryl intermediate (compound II).  Compound II then performs a 1-
electron oxidation of tryptophan, giving a radical which recombines with NO2 to give the 
product.  In pathway (2), heterolytic decomposition of the ferric peroxynitrite intermediate 
gives the ferric-hydroxide resting state and NO2+, which reacts with tryptophan by 
electrophilic aromatic substitution.   
A recently characterized reaction of uncertain mechanism is P450-catalyzed 
synthesis of alkanes from fatty aldehydes to form insect protective coatings.20 In contrast to 
other known P450-catalyzed decarboxylation or decarbonylation reactions,14 the product 
here is a fully saturated alkane.  Although strong evidence that a P450 was responsible for 
this reaction was first presented in the 1990s,21 only recently has the specific P450 enzyme 
been identified.20 
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Manipulating conserved features enables non-natural chemistry 
The diverse set of naturally occurring P450 reactions has proven a rich source of 
inspiration for the field of biomimetic oxidation in synthetic chemistry.  In an interesting 
reversal of roles, several classic papers as well as more recent works have shown that 
P450s can catalyze reactions first discovered by synthetic chemists.  Unlike natural P450 
reactions, which rely on various reactive oxygen intermediates, these new P450 reactions 
stem from alternative reactive species created through the use of activated reagents such as 
diazo compounds and azides. Some of the inspiration for non-natural P450 reactions came 
from the rich literature on P450 model complexes. Originally synthesized as functional or 
spectroscopic mimics of P450 enzymes, model P450 complexes (i.e., iron-porphyrins) were 
later found to catalyze several reactions distinct from oxygen transfers.  Breslow and 
Gelman first demonstrated that iron-tetraphenyl porphyrin model complexes could catalyze 
intra- and intermolecular nitrene transfers to form benzosultams and substituted 
cyclohexanes when provided with iminoiodinane nitrene precursors.22  Following up on 
this, Dawson and coworkers found that rabbit liver P450 enzymes could catalyze low levels 
(< 5 total turnovers, TTN) of the same reactions that had been described for the synthetic 
P450 model.23 
More recently, our group demonstrated several new P450 reactions that had 
previously been shown only for metalloporphyrins.  It has been known since the 1990s that 
iron porphyrins catalyze the reaction of olefins with diazo carbene precursors to yield 
cyclopropanes 24.  Metalloporphyrin-catalyzed cyclopropanation is thought to proceed via a 
metal-carbenoid intermediate, analogous to P450 epoxidations that proceed through 
compound I.  However, it was only recently shown by Coelho et al.25 that this reaction 
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could be catalyzed at low levels by hemin in water as well as by several heme proteins, 
including P450BM3, although at levels even lower than free hemin. The selectivities of most 
of the heme proteins mirrored the trans-selectivity of hemin for the cyclopropanation of 
styrene with ethyl diazoacetate.  P450BM3 showed very low activity, but in contrast to the 
other heme proteins produced the cyclopropane product with low but measurable 
enantioselectivity.  Mutations in P450BM3, including at highly conserved residues such as 
the active site threonine T268, which when mutated to alanine dramatically improved the 
productivity as well as the diastereo- and enantioselectivity of this reaction (Figure 3A).  
Although in natural P450s, this conserved active site threonine acts as a proton shuttle, for 
non-natural chemistry, mutation of T268 to less bulky alanine presumably relieves steric 
impediments to reactivity, as evidenced by strong alterations in the stereoselectivity of 
cyclopropanation; future studies may shed light on the effect of this mutation by assaying 
alternative substitutions at this position.  Enzyme engineering could even overcome the 
natural selectivity of the prosthetic group to achieve >90% cis selectivity. And, while free 
hemin gives a racemic mixture of products, the P450BM3 cyclopropanation catalysts 
exhibited enantioselectivites of up to 97%.  In a second publication, Coelho and coworkers 
demonstrated that mutation of the axial coordinating cysteine, universally conserved among 
P450s, to serine was highly activating, particularly in vivo (vide infra).26 The strong effect 
of axial ligand substitution was attributed in part to the significant increase in reduction 
potential (>100 mV increase) for the serine-ligated enzyme, facilitating reduction to the 
active ferrous state.  Axial thiolate ligation, absolutely essential for monooxygenation, is 
unnecessary for this non-natural reaction.  Whereas thiolate ligation is important for O–O 
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bond scission, no such strong electron donation is required to decompose the less-stable 
diazo substrates employed by Coelho et al. 
Another metalloporphyrin reaction shown to be catalyzed by P450s is C–H 
amination from azides as nitrene sources (Figure 3B).27 The iminoiodinane precursors that 
Dawson and coworkers had used to obtain low levels of C–H amination with P450s23 are 
problematic due to their insolubility in protein-compatible solvents.  Thus we tested the 
more atom-efficient and convenient azide-based nitrene precursors.  In spite of the fact that 
azide-based C–H amination reactions have been found to be markedly less efficient with 
iron-porphyrins (as compared to cobalt or ruthenium complexes) and require high 
temperatures and anhydrous conditions,28 we found that wild-type P450BM3 could catalyze 
low levels of intramolecular C–H amination to yield benzosultams.27  As found for 
cyclopropanation, enzyme engineering could improve the enantioselectivity and activity of 
the new C–H amination enzymes.  Indeed several of the mutations that increased 
cyclopropanation activity (at the active site threonine and axial cysteine) were found to 
strongly modulate C–H amination activity, leading to catalysts that were capable of 
catalyzing several hundred turnovers in vitro and roughly double that amount in vivo.  Here 
again, mutation to the conserved axial cysteine was highly activating: its positive effect on 
C–H amination in vitro was even greater than that observed for cyclopropanation.  
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Figure 3.  Several recent examples of non-natural P450 reactions: (A) cyclopropanation of 
styrene catalyzed by P450BM3 variants,25 (B) intramolecular C–H amination catalyzed by 
P450BM3 variants expressed in whole cells27 and (C) intermolecular carbene insertion into 
N-H bonds yielding secondary amines.29 
 
In another approach to P450-catalyzed C–N bond formation, Wang et al. have 
shown that engineered P450 enzymes can also catalyze carbene N-H insertions.29 The 
reaction of ethyl diazoacetate with a diverse set of amine acceptors was found to proceed 
with high turnover numbers.  Although many other C–N bond forming methodologies lead 
to product mixtures via multiple nucleophilic additions, the enzyme-catalyzed N-H 
insertions gave only the desired secondary amines (Figure 3C).  Of note is that free hemin 
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produces a mixture of secondary and tertiary amines, which emphasizes the important 
role of the enzyme in regulating substrate access to the reactive center.  
An interesting aspect of these new reactions is that both cyclopropanation and C–H 
amination proceed well in whole cells.  P450BM3-derived cyclopropanation catalysts, in 
particular, were more than six-fold faster when used in whole cells (on a per enzyme basis) 
and catalyzed more than 60,000 total turnovers under saturating substrate concentrations.26 
Thus the enzyme is as good as any transition metal catalyst reported to date. Although 
NADPH-driven heme reduction in vitro requires P450BM3’s reductase domain, in whole 
cells the reductase was not strictly necessary: even the isolated heme domain could catalyze 
over 1,000 total turnovers of styrene cyclopropanation.  In the reducing environment of 
anaerobic whole cells, other electron donors apparently can facilitate reduction to the active 
ferrous state.  For C–H amination the effect of carrying out reactions in whole cells was 
less profound (roughly two-fold higher activity), perhaps due to the higher levels of azide 
reduction (which competes with C–H amination) in whole cells than in vitro.   
A simplifying feature of enzyme-catalyzed carbene and nitrene transfers is the 
enzyme’s decreased dependence on the reductase domain for activity. For C–H amination 
and carbene transfers, although initial reduction to ferrous heme is necessary, after bond 
formation the heme is returned to the active ferrous state, thus eliminating the need for 
stoichiometric NADPH.  Decreased dependence on the reductase may also prove to be 
problematic, as it may lead to the generation of reactive carbon or nitrogen species in the 
absence of substrate, which for stronger electrophiles may lead to heme or protein 
destruction. 
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An interesting lesson from these efforts to generate enzymes for whole new 
reactions is that conserved residues whose function was highly specific to the chemistry 
catalyzed by the natural enzyme became particularly important for tuning the new 
activities.  The active site threonine, which normally helps to catalyze O–O bond scission 
via protonation, and the axial coordinating cysteine, whose importance in oxygenation 
reactions is profound,7c can both be substituted to greatly increase activity for C–H 
amination and cyclopropanation (and abolish monooxygenase activity).  Many other 
protein residues contribute to oxygen activation in P450s, and it is likely that at least some 
can be mutated to further enhance non-natural reactivity.  As observed with natural P450 
enzymes, enhancing the reactivity of enzyme-carbenoid and nitrenoid intermediates may 
facilitate an expanded catalytic scope for these new chemistries.   
 
Conclusions 
What information can be gleaned from the diverse natural and non-natural 
chemistry catalyzed by P450 enzymes that might inform other efforts to genetically encode 
new reactions?  As noted above, much of the natural diversity of P450 chemistry is driven 
by the reactive nature of oxygen activation intermediates.  In this vein, it is worth noting 
that many other natural enzymes are capable of generating highly reactive species, such as 
other oxygenase enzymes (di-iron monooxygenases, Rieske monooxygenases, etc.), radical 
SAM enzymes, and adenosylcolbalamin-dependent enzymes, among others.30  Although 
they may prove more difficult to engineer than P450s, these enzymes should not be 
overlooked in the search for new biocatalytic transformations.  
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For recent non-natural P450 chemistry, the reactive intermediates are derived 
from the reaction of enzyme with synthetic reagents.  That these reactions do not require 
the sophisticated P450 catalytic cycle with its well-timed reductions and bond cleavages 
can be attributed to the activated nature of the reagents, which undergo relatively facile 
decomposition to yield reactive carbon and nitrogen species. Exploring the reactions of 
synthetic reagents with natural enzymes has proven fruitful for finding new genetically 
encoded catalysts in other contexts31 and is likely to bring more synthetic chemistry into 
biology. While the reactivity of a free prosthetic group is not necessarily predictive of 
activity within an enzyme, for each reaction type we explored thus far,25,26-27,29 free heme 
was found to give at least some basal activity with most (though not all) substrates under 
the assay conditions. Thus investigations of metal/cofactor-reagent pairs may yield useful 
starting points for identifying possible new enzyme reactivities.  Of course, what is 
different from past efforts23 is the availability of enzyme engineering tools such as directed 
evolution, which can reliably improve even very low activities, especially when the 
activities are exhibited by an (evolvable) enzyme rather than some other protein 
framework.   
Although non-natural chemistries that rely on synthetic reagents may be 
challenging to employ within cellular biosynthetic pathways, a great deal of useful 
biocatalysis is conducted in vitro32 where access to the synthetic reagent is not a problem.  
Current efforts to develop biosynthesis in cell-free extracts33 could allow for relatively 
straightforward integration of non-natural prosthetic groups and reagents in biosynthetic 
pathways.  Thus, working within the constraints of biology may ultimately prove 
unnecessary—even for enzyme engineers. 
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C h a p t e r  2  
ENANTIOSELECTIVE INTRAMOLECULAR C–H AMINATION CATALYZED BY 
ENGINEERED CYTOCHROME P450BM3 ENZYMES 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as J. A. McIntosh, P. S. Coelho, C. C. Farwell, Z. J. Wang, J. C. 
Lewis, T. R. Brown F. H. Arnold “Enantioselective Intramolecular C–H Amination 
Catalyzed by Engineered Cytochrome P450 Enzymes in vitro and in vivo.” in Angewandte 
Chemie Int. Ed. 2013, 52, 9309-9312.   I contributed to all characterization of enzymes, 
including protein expression and purification, in vitro and in vivo reactions, and 
quantification of all enzyme reaction products.  J.A.M., P.S.C., Z.J.W., and T.R.B. 
performed chemical syntheses and characterization of standards.  
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Abstract 
 
The ease with which cytochrome P450 enzymes can install oxygen atoms within otherwise 
unreactive chemical structures has fascinated scientists from all branches of chemistry.  
Although many studies have examined the use of protein engineering to modify the 
substrate specificity of these enzymes, few studies have examined the possibility of 
catalyzing entirely unnatural reactions with P450s.  Here, inspired by innovative work in 
synthetic porphyrin chemistry, we show that engineered variants of P450 BM3 catalyze C–
H amination upon reaction with arylsulfonyl azides.  Wild-type BM3 enzyme exhibits 
some activity, but it is greatly enhanced by the mutation of two residues that are highly 
conserved within P450s, demonstrating a strong ‘tuning’ effect of enzyme residues on the 
efficiency of the reaction.  These new nitrene-insertion enzymes are also highly active in 
vivo in E. coli cells, where they catalyze several hundreds of turnovers.  
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Main Text 
Iron containing monooxygenases play diverse roles in nature, ranging from the 
primary metabolic functions of alkane hydroxylases to the xenobiotic detoxification and 
secondary metabolic roles of cytochrome P450 enzymes.1 Common to these enzymes is 
the ability to reductively activate molecular oxygen to generate highly electrophilic 
oxygen species, whose reactivity is comparable with that of ‘oxenes’ (oxygen atoms 
containing six-valence electrons).2 P450 enzymes in particular possess the remarkable 
ability to insert oxygen atoms at virtually any position within otherwise unreactive carbon 
skeletons, leading to the synthesis of alcohols or epoxides in diverse natural products.  
Whereas enzymes are capable of inserting oxygen atoms into even unactivated C–
H bonds, the sites into which nitrogen can be incorporated are more constrained. 
Transaminases, ammonia lyases, and amino acid dehydrogenases, for example,3 target 
oxidized or otherwise chemically activated carbons for reaction. Enzymes that catalyze 
the concerted oxidative amination of C–H bonds are apparently absent from nature's 
repertoire of chemical catalysts.  
 Synthetic chemists, who are not limited to biologically accessible reagents and 
metals, have developed highly useful methods for the oxidative formation of C–N  
bonds.4 These C–H amination reactions often proceed through a nitrenoid intermediate 
that has no parallel in natural enzymes. Although these reactions do not require 
preoxidized or otherwise activated carbon atoms, they do require specialized nitrene-
precursors such as azides, haloamines, or iminoiodinanes. Of the many transition-metal 
catalysts based on Rh, Ru, Mn, Co, and Fe that catalyze intra- and intermolecular C–H 
amination, we were especially interested in the metal-porphyrin systems,5 which react 
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with iminoiodinanes in the +3 oxidation state to catalyze nitrene transfers that are 
isoelectronic with the well-established formal oxene transfer reaction of ferric-P450 
enzymes with iodosylbenzene.5a,6  Trace levels (3 total turnovers; TTNs) of 
intramolecular C–H amination were reported more than 25 years ago for mammalian 
cytochrome P450 preparations reacting with iminoiodinanes.7 We decided to revisit the 
possibility of finding or engineering an enzyme catalyst for this useful and challenging 
transformation.  
 Iminoiodinanes, however, are problematic for biocatalytic application, given their 
polymeric nature8 and insolubility9 in aqueous media. As an alternative to 
iminoiodinanes, we decided to focus on the synthetic reaction of sulfonylazides with 
reduced (+2 oxidation state) metal porphyrins.10 We reasoned that such a 
"chemomimetic" approach to achieving direct C–H to C–N conversion could provide a 
biocatalytic route to amines and amides using biochemically compatible and atom-
efficient azide-based nitrene precursors, with the usual enzyme advantages of selectivity 
and mild reaction conditions. Here we report the first highly active enzyme catalysts of 
C–H amination. 
 
 
Scheme 1. Initial reaction screening substrate and products 
 
S N3
O O
NH
S
O OS NH2
O O
+
*
0.5 mol% enzyme
2.5% DMSO
0.1 M KPi pH 8.0
anaerobic, 24hr, rt
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 In initial experiments, we tested a panel of 24 purified cytochrome P450BM3 
variants developed for monooxygenation reactions. Enzymes were reacted with 2,4,6-
triethylbenzene-1-sulfonylazide (1) under anaerobic, reducing conditions at an enzyme 
loading of 0.5 mol% in aqueous media (phosphate buffer, 2.5% v/v DMSO). Most 
reactions gave sulfonamide 2 as the major product, though all of the tested enzymes, 
including wild-type (4 TTN), yielded small amounts of the C–H amination product, 3. 
The most active enzyme for C–H amination in the initial screen contained only a single 
mutation (T268A) relative to wild-type P450BM3. The T268A mutation was recently 
shown to promote P450BM3-catalyzed carbene transfers yielding cyclopropanes.11 Thus, 
in spite of the significant differences between carbene and nitrene chemistry, we 
proceeded to test several P450BM3-based cyclopropanation catalysts, including several 
serine-heme ligated ‘P411’12 enzymes (so called because the Soret peak in the ferrous 
CO-bound spectrum is shifted to 411 nm rather than 450 nm for cysteine ligated 
enzymes) in which the axial coordinating cysteine C400, absolutely required for 
monooxygenation activity, is mutated to serine. The most active enzyme here was the 
serine-heme ligated P411BM3-CIS (14 mutations from wild-type), which also contained 
the T268A mutation and supported over 140 total turnovers (73% yield of 3 by HPLC). 
Variant P450BM3-CIS, which lacks the C400S mutation at the axial heme ligand, was 
significantly less active (9 TTN), indicating that serine-heme ligation strongly enhances 
BM3-catalyzed C–H amination. The P450BM3-C400S single mutant (P411BM3) also 
exhibited markedly improved activity (49 TTN) relative to its cysteine-ligated 
counterpart, P450BM3 (4 TTN). To clarify the roles of the T268A and C400S mutations in 
BM3-catalyzed amination, we performed further experiments at 0.1 mol% catalyst 
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loading with the P450BM3-T268A and P411BM3 single mutants as well as the 
T268A/C400S double mutant in reaction with sulfonyl azide 1 (Table 1). We found that 
the T268A and C400S mutations combined to yield a highly active enzyme (120 TTN for 
the double mutant versus 310 TTN for P411BM3-CIS, Table 1), indicating that the T268A 
and C400S mutations were major contributors to the high activity of P411BM3-CIS. In 
fact, reverting the T268A mutation in P411BM3-CIS markedly reduced activity (82 TTN). 
Table 1. Comparison of activities (TTN) and enantioselectivities of purified P450 and 
P411 variants (0.1 mol % catalyst loading) for the reaction of azide 1 to sulfonamide 2 
and sultam 3. 
 
a TTN = total turnover number. b (S-R)/(S+R).  n.d. = not determined. Reaction 
conditions described in the supplementary materials.  TTNs and enantioselctivities 
determined by HPLC analysis. 
 
Control experiments revealed that the enzyme-catalyzed reaction was inhibited by 
carbon monoxide, air, and heat denaturation of the enzyme, all of which suggests that 
catalysis occurs at the enzyme-bound heme (Table S2). Hemin also was capable of 
catalyzing this reaction when reduced with dithionite (Figure 1). However, whereas 
enzyme reactions with prochiral substrate 1 resulted in asymmetric induction (up to 67% 
ee, Table 1), reaction with hemin unsurprisingly yielded only racemic 3, strongly 
In vitro catalyst TTNa % eeb 
P450BM3 2.1 n.d. 
P450BM3-T268A 15 36 
P411BM3 32 20 
P411BM3-T268A 120 58 
P411BM3-CIS 310 67 
P411BM3-CIS-A268T 82 47 
P411BM3-CIS-T438S 383 73 
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suggesting that BM3-catalyzed amination occurs within the chiral environment of the 
enzyme active site. Addition of sub-stoichiometric amounts of NADPH was sufficient for 
activity (Table S3), supporting the hypothesis that ferrous-heme is the azide-reactive 
state, akin to P450-catalyzed cyclopropanation.11 Dithionite could be used in place of 
NADPH to drive catalysis, where its effect was comparable to that of NADPH for both 
cysteine- and serine-ligated enzymes P450BM3-T268A and P411BM3-T268A (Table S4), 
indicating that reduction to ferrous heme was not limiting.  
To examine the effect of C–H bond strength on amination activity, P411BM3-CIS 
and P411BM3-T268A were reacted with the trimethyl and triisopropyl analogs of 1 
(substrates 4 and 6, respectively). The desired benzosultam products were obtained, 
though the productivity was lower with both substrates (Figure 1). Free hemin activity 
was inversely correlated with the substrate C–H bond strength, showing no measurable 
activity on substrate 4, minimal activity on substrate 1 (3 TTN), and the highest activity 
on substrate 6 (55 TTN). The differing patterns of activity observed with hemin and 
enzyme-catalyzed reactions suggest that the enzyme itself plays a critical role in 
catalyzing C–H bond formation beyond providing a chiral active site that guides the 
stereochemical outcome of the reaction. In particular, enzyme reactions with triethyl and 
trimethyl sulfonylazide substrates 1 and 4 were markedly more productive than the 
corresponding hemin reactions. The reduced activity of the enzyme toward triisopropyl 
substrate 6 suggests that the active site structure currently favors smaller substrates, 
though it is likely that this can be modulated by further enzyme engineering.  
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Figure 1. Substrate selectivity of P411 enzymes compared with free hemin.  Compounds 
used to test the dependence of amination activity on C–H bond strength in reaction 
catalyzed by enzyme (0.1 mol%) or hemin (1 mol%) are shown.  Reaction conditions are 
described in the Supporting Information. 
 
To determine whether this new reactivity could be exploited in vivo, we next 
investigated whether these enzymes expressed in intact E. coli cells could catalyze 
amination reactions when provided with azide substrate. Remarkably, both the P411BM3-
T268A and P411BM3-CIS enzymes were highly active on 1, catalyzing hundreds of 
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turnovers (245 TTN, 89% ee P411BM3-T268A, 680 TTN, 60% ee P411BM3-CIS) under 
anaerobic conditions with added glucose (Tables 2, S4).  
Table 2. Comparison of C–H amination activities (TTN) of intact E. coli cells expressing 
P450 and P411 variants 
 
a TTN = total turnover number. b (S-R)/(S+R). n.d. = not determined.  Reaction 
conditions described in Supporting Information.  
 
Lyophilized cells containing P411BM3-CIS could also support catalysis, with 
productivity similar to freshly-prepared cell suspensions (750 TTN, 61% ee). 
Enantioselectivity was comparable or enhanced for whole-cell catalysts relative to 
purified enzymes (Table 2). Including the previously characterized T438S mutation in 
P411BM3-CIS strongly increased enantioselectivity (430 TTN, 86% ee).11,13 Optimization 
of expression conditions increased the productivity of whole-cell C–H amination 
catalysts, enabling conversions of nearly 70% in small-scale reactions (Table S6). 
Inspired by the simplicity of employing whole cells as amination catalysts, we performed 
a preparative scale reaction (50 mg) using anaerobic resting cells expressing the P411BM3-
CIS-T438S catalyst, affording sultam 3 (77% yield by HPLC, 69% isolated yield, 87% 
ee).  
In vivo catalyst [Enzyme] (µM) % Yield 3 TTNa % eeb 
pCWori-empty 0 0 0 n.d. 
P450BM3 6.6 0.5 5.1 n.d. 
P450BM3-T268A 5.8 7.8 26 84 
P411BM3 4.3 6.7 29 16 
P411BM3-T268A 2.2 30 250 89 
P411BM3-CIS 1.4 46 680 60 
P411BM3-CIS-T438S 2.7 58 430 87 
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The beneficial effects of the T268A and C400S mutations for C–H amination is 
striking in that both residues play critical roles in P450-catalyzed monooxygenation.14 
While important for protonation of iron-peroxo intermediates that occur during dioxygen 
activation, T268 may sterically hinder binding of bulkier azide substrates in C–H 
amination. Consistent with a steric role, the T268A mutation enhances the 
stereoselectivity of C–H amination; it also strongly impacts diastereo and 
enantioselectivity of styrene cyclopropanation.11 The C400S mutation is not necessary for 
dithionite-driven in vitro cyclopropanation, and its strong effect in vivo can be attributed 
to the higher reduction potential of the serine-ligated heme, which facilitates reduction by 
NADPH.12 In contrast, here we find that the C400S mutation is absolutely necessary for 
high levels of in vitro amination activity (Table 1). This effect persists even when 
dithionite is used as a reductant (Table S4), suggesting that the C400S mutation does not 
simply facilitate NADPH-driven reduction to the active ferrous state, but rather exerts a 
strong effect on subsequent steps of the reaction. That mutations to both T268 and C400 
appear necessary for enzymatic C–H amination suggests that naturally occurring P450s, 
in which these two residues are highly conserved, will likely be poor catalysts of C–H 
amination.  
Many enzyme-catalyzed reactions, such as ketoreduction, monooxygenation, and 
transamination, are increasingly useful in chemical synthesis,15 and applications of these 
and other naturally-occurring reaction types will continue to develop. However, it is no 
longer necessary to limit biocatalysis to reactions that have natural antecedents.11,16 
Rather, the scope of biocatalysis can be expanded by directing natural enzymes to imitate 
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the artificial, accessing whole new chemistries by judicial choice of reaction 
conditions, synthetic reagents, and protein engineering.  
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1. Materials and Methods  
General. Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, Acros) and used without further 
purification. Silica gel chromatography purifications were carried out using AMD Silica 
Gel 60, 230-400 mesh. 1H and 13C NMR spectra were recorded on either Varian Inova 500 
MHz or 600 MHz instruments in CDCl3, and are internally referenced to residual solvent 
peak. Optical rotation values were measured on a Jasco J-2000 polarimeter.  Reactions 
were monitored using thin layer chromatography (Merck 60 silica gel plates) using an UV-
lamp for visualization or stains where indicated.  
Analytical high-performance liquid chromatography (HPLC) was carried out using 
an Agilent 1200 series, an UV detector, and a Kromasil 100 C18 column (Peeke Scientific, 
4.6 x 50 mm, 5 µm). Semi-preparative HPLC was performed using an Agilent XDB-C18 
(9.4 x 250 mm, 5 µm).  Analytical chiral HPLC used a Chiralpak AD-H column (Daicel, 
4.6 x 150), while preparative chiral HPLC used a Chiralpak AD-H column (Daicel, 21 x 
250 mm, 5 µm). Azides 1 and 4, and benzosultam standards 3, 5, and 7 were prepared as 
reported.17 Azide 7 is commercially available (Sigma, 723045-1G). These standards were 
used in co-injection experiments to determine the authenticity of benzosultams. 
Enzymatically-produced benzosultam 3 was prepared as described below and was 
characterized by NMR (1H and 13C).    
pCWori was used as a cloning and expression vector for all enzymes described in 
this study. Site-directed mutagenesis of P411BM3-CIS to yield P411BM3-CIS-A268T was 
performed via overlap extension PCR, followed by digestion of vector and PCR products 
with BamHI and SacI.  The PCR products were gel purified and ligated into digested 
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pCWori using T4 ligase (NEB, Quickligase).  Primer and vector sequences available 
upon request.   
 
Determination of P450/P411 concentration.  Concentration of P450 or P411 enzymes 
was determined from ferrous carbon monoxide binding difference spectra using previously 
reported extinction coefficients for cysteine-ligated (ε = 91,000 M-1cm-1) and serine-ligated 
enzymes (ε = 103,000 M-1 cm-1).18  
 
Table S1.  Mutations (relative to wild-type P450BM3) in enzymes used in this study. 
 
Protein expression and purification. Enzymes used in purified protein experiments were 
expressed from E. coli cultures transformed with plasmid encoding P450 or P411 variants.  
BL21(DE3) was used for expression of P411BM3-CIS, while DH5α was used as an 
expression host for all other enzymes.  Expression and purification was performed as 
described elsewhere,19 with the exception that the agitation rate was lowered to 150 RPM 
for P411 after induction. Following expression, cells were pelleted and frozen at -20 °C. 
For purification, frozen cells were resuspended in lysis buffer (25 mM tris pH 7.5, 4 mL/g 
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of cell wet weight) and disrupted by sonication (2 x 1 min, output control 5, 50% duty 
cycle; Sonicator 3000, Misonix, Inc.). To pellet insoluble material, lysates were centrifuged 
at 24,000xg for 0.5 h at 4 °C. Cleared lysates were then purified on a Q Sepharose column 
(5 mL HiTrapTM Q HP, GE Healthcare, Piscataway, NJ) using an AKTAxpress purifier 
FPLC system (GE healthcare).  P450 or P411 enzymes were then eluted on a linear 
gradient from 100% buffer A (25 mM tris pH 8.0), 0% buffer B (25 mM tris pH 8.0, 1 M 
NaCl) to 50% buffer A/50% buffer B over 10 column volumes (P450/P411 enzymes elute 
at around 0.35 M NaCl).  Fractions containing P450 or P411 enzymes were pooled, 
concentrated, and subjected to three exchanges of phosphate buffer (0.1 M KPi pH 8.0) to 
remove excess salt.  Enzyme concentrations were determined by CO binding difference 
spectra as described above. Concentrated proteins were aliquoted, flash-frozen on 
powdered dry ice, and stored at -20 °C until later use.  
 
2. Confirmation of Enzymatic Activity 
Controls to confirm the enzymatic amination activity of variant P411BM3-T268A.  
Small-scale reactions (400 µL total volume) were set up and worked up as described above.  
Control reactions were performed with both the holoenzyme (BM3 with covalently linked 
reductase domain) and the isolated heme domain.  Reactions denoted by complete system 
(CS) indicate holo enzyme with reaction conditions as displayed in the scheme below.  
Reactions of the complete system with heme domain (CS heme) included 2 mM Na2S2O4 
rather than NADPH unless otherwise indicated in Table S2. Carbon monoxide (CO) 
inhibited and heat-denatured enzyme controls were performed as previously described.11 
Buffer for the CO controls was supplemented with 2 mM Na2S2O4 in both holoenzyme and 
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heme domain experiments.  For the hemin experiment, 0.8 mL of a hemin solution (1 
mM in 50% DMSO-H2O) was added to a final concentration of 2 mM to afford a direct 
comparison with the enzyme reactions.  TTNs and enantioselectivities were determined as 
described above.   
Table S2. Controls experiments for variant P411BM3-T268A. Conditions are as 
described in the supporting methods. Reactions denoted by complete system (CS) indicate 
holo enzyme with reaction conditions as displayed in the above scheme.  Reactions of the 
complete system with heme domain (CS heme) included 2 mM Na2S2O4 rather than 
NADPH unless otherwise indicated in the table. 
  
 
aPercent residual activity (CS = 100%). *%ee=(S-R)/(S+R) 
 
S
O O
N3 NH
S
O O
0.1 mol% P411BM3-T268A
0.1 M KPi pH 8.0
2.5 % (v/v) DMSO
∗
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3. Reaction Optimization and Conditions 
Typical procedure for small-scale amination bioconversions under anaerobic 
conditions using purified enzymes. Small-scale reactions (400 µL) were conducted in 2 
mL crimp vials (Agilent Technologies, San Diego, CA) containing buffer (0.1 M potassium 
phosphate pH 8.0), enzyme (0.1-0.5% catalyst loading), and oxygen depletion mixture 
(10X stock solution containing 14,000 U/mL catalase, 1,000 U/mL glucose oxidase 
dissolved in 0.1 M KPi pH 8.0). Enzyme (P450 or P411) and oxygen depletion mixture 
were added to the vial with a small stir bar before crimp-sealing. Portions of phosphate 
buffer (190 µL, 0.1 M, pH = 8.0), glucose (40 µL, 250 mM) and NADPH (40 µL, 20 mM), 
or multiples thereof, were combined in a larger crimp sealed vial and degassed by sparging 
with argon for at least 5 min. In the meantime, the headspace of the sealed 2 mL reaction 
vial with the P450 solution was made anaerobic by flushing argon over the protein solution 
(with no bubbling). The buffer/reductant/glucose solution (270 µL) was syringed into the 
reaction vial with continuous argon purge of the vial headspace.  An arylsulfonyl azide 
solution in DMSO (10 µL, 80 mM) was added to the reaction vial via a glass syringe, and 
the reaction was left stirring for 24 h at room temperature under positive argon pressure.  
Final concentrations of the reagents were typically: 2 mM arylsulfonyl azide, 2 mM 
NADPH, 25 mM glucose, 2 or 10 µM P450. Reactions were quenched by adding 30 µL 3 
M HCl under argon. To the vials were then added acetonitrile (430 uL) and internal 
standard (o-toluenesulfonamide 10 mM in 50% acetonitrile 50% water, 1 mM final 
concentration).  This mixture was then transferred to a microcentrifuge tube, and 
centrifuged at 17,000xg for 10 minutes.  A portion (20 µL) of the supernatant was then 
analyzed by HPLC. For LC-MS analysis, the quenched reaction mixture was extracted 
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twice with ethyl acetate (2 x 350 µL), dried under a light argon stream, and resuspended 
in 50% water-acetonitrile (100 µL).  For chiral HPLC the reactions were extracted as above 
with ethyl acetate, dried and resuspended in DMSO (100 µL), and then C18 purified as 
described above.  The C18 purified material was dried, and resuspended in acetonitrile, and 
then injected onto the chiral HPLC system for analysis.  Sultam formation was quantified 
by comparison of integrated peak areas of internal standard and sultam at 220 nm to a 
calibration curve made using synthetically produced sultam and internal standard.    
 
Table S3: Dependence of holoenzyme activity on NADPH concentration.  Small-scale 
reactions (400 µL) were assembled and worked up as described above. NADPH 
concentration was varied within the concentration range of sultam product formation to 
assess stoichiometry of iron reduction in the enzyme-catalyzed reactions. The P411BM3-CIS 
enzyme was used at 0.2 mol % loading (4 µM) relative to azide substrate 1 (2 mM) with 
indicated reductant concentration, 0.1 M KPi pH 8.0, and 2.5 % (v/v) DMSO co-solvent.     
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Table S4: Comparison of NADPH and dithionite in reaction of P450BM3-T268A and 
P411BM3-T268A with azide 1.  Small scale reactions containing either NADPH (2 mM) or 
dithionite (2 mM) as reductant, enzymes were used at 0.1 mol% loading (2 µM) relative to 
azide substrate 1 (2 mM) 0.1 M KPi pH 8.0, 2.5 % DMSO co-solvent.  Enzyme activities 
are given in TTNs.   
 
 
 
Typical procedure for small-scale amination bioconversions under anaerobic 
conditions using whole cells.  E. coli BL21(DE3) cells containing P450 or P411 enzymes 
were expressed and prepared as described elsewhere.12 Following expression, cells were 
resuspended to an OD600 of 30 in M9 salts lacking NH4Cl (M9-N), and then degassed by 
sparging with argon in a sealed 6 mL crimp vial for at least 0.5 h.  Separately, glucose (250 
mM dissolved in 1X M9-N, 40 µL, or multiples thereof) was degassed by sparging with 
argon for at least 5 minutes.  The oxygen quenching mixture was added to sealed 2 mL 
crimp vials containing stir bars and the headspace of the vials was purged with argon for 5 
minutes, at which time glucose, and then cells were added by syringe.  Substrate (80 mM 
arylsulfonyl azide, 10 µL in DMSO) was added via syringe, and the reactions were stirred 
at room temperature for 24 h under positive argon pressure.  Reactions were quenched in a 
manner identical to reactions containing purified enzymes, as described above.  For chiral 
NH
S
O O
P411 or P450 enzyme
NADPH or Na2S2O4
S
O O
N3
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HPLC, the reactions were extracted and purified in an identical manner as for reactions 
that employed purified enzymes.  Lyophilized intact cells containing sucrose as a 
cryoprotectant were prepared as described elsewhere.12 The resulting cell powder, 
containing expressed P411BM3-CIS (26 mg), was added along with a stir bar to a 2 mL 
crimp vial and then sealed.  The headspace of the vial was degassed, oxygen quenching 
system (40 µL) was added via syringe, followed by degassed glucose (250 mM, 40 µL), 
M9-N (310 µL), and finally substrate (80 mM 1, 10 µL). Lyophilized cell reactions were 
stirred for 24 h at room temperature, then quenched and analyzed as described above.   
 
Table S5.  Comparison of amination activity of whole-cell catalysts.  This table 
provides additional data regarding in vivo catalysts, some of which are also presented in 
Table 2 in the main text.   
 
 
Optimization experiments for whole-cell reactions. Different media conditions were 
tested according to the standard procedure described above, except that the seed culture 
was grown in LB rather than M9Y, and the expression culture was grown in the alternative 
medium. Tested media TB+power-mix, C-*, and FB were selected based on previously 
published work concerning P450 expression.20 Hyperbroth was purchased from Athena 
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Environmental Sciences (Baltimore, MD) and used according to the manufacturer’s 
instructions.   
 
Table S6. Effect of growth medium on productivity of forming sultam 3. Expression 
conditions were varied as described in the supporting information. Yields determined by 
HPLC quantification.   
 
 
Preparative-Scale Bioconversions. The preparative reaction was scaled up proportionally 
from small-scale reactions.  E. coli BL21 cells containing P411BM3-CIS (OD600 30, 90 mL 
in M9-N) were sparged with argon for 45 minutes in a round bottom flask (250 mL) 
containing a stir bar.  Separately, glucose solution (250 mM, 11.6 mL) was sparged with 
argon in a conical flask.  The oxygen quenching mixture (10X, 11.6 mL) was degassed in a 
conical flask that was placed under high vacuum until slight foaming occurred (1-2 s) and 
then back-filled with argon; this sequence was repeated several times.  Sparged glucose 
solution was then added to the anaerobic cell suspension via syringe, followed by the 
oxygen quenching system (at which time sparging was ceased though the mixture was 
maintained under positive argon flow).  Finally, substrate 1 (80 mM, 2.9 mL DMSO) was 
added dropwise via syringe, and the reaction was stirred for 24 h at room temperature 
under positive argon pressure.  To quench the reaction, dilute HCl (3 M, 8.7 mL) and 
acetonitrile (125 mL) were added.  Cell debris was pelleted by centrifugation (8000 x g, 10 
  
41 
minutes), and the supernatant was then extracted with ethyl acetate (2 x 250 mL).  
Solvent removal in vacuo left a brown oil (1 g), which was purified on silica gel via a 
stepwise elution (hexanes, 90/10 hexanes/ethyl acetate, 80/20 hexanes/ethyl acetate, 70/30 
hexanes/ethyl acetate, ethyl acetate). Fractions containing 3 (as judged by TLC developed 
in 90/10 hexanes/ethyl acetate and stained with Cl2/O-tolidine) were pooled and solvent 
was removed in vacuo.  The resulting material was further purified on silica gel via an 
isocratic elution (50/50 hexanes/ether) affording 3 (38.6 mg, 69% yield), which was 
established by chiral HPLC as well as 1H and 13C NMR.  Spectra are presented below.    
 
 
4. Synthetic Procedures 
Synthesis of Substrates and Standards. Synthesis of azide substrates and benzosultam 
standards was accomplished as previously described; their spectra matched those 
previously reported.17  
2,4,6-triethylbenzenesulfonyl azide (1) 1H NMR (500 MHz, CDCl3): d 7.07 (2H, 
s), 3.06 (4H, q, J = 7.39 Hz), 2.66 (2H, q, J = 7.59 Hz), 1.29 (6H, t, J = 7.41 Hz), 1.26 (3H, 
t, J = 7.65 Hz); 13C NMR (125 MHz, CDCl3): d 150.9, 146.5, 132.5, 129.8, 28.7, 28.5, 
17.0, 15.0.   
 
Synthetic (3) 1H NMR (500 MHz, CDCl3): d 7.13 (1H, s), 6.98 (1H, s), 4.69 (m, 
1H) 4.62 (s, 1H), 2.99 (2H, q, J = 7.57 Hz), 2.71 (2H, q, J = 7.62 Hz), 1.59 (3H, d, J = 6.69 
Hz), 1.35 (3H, t, J = 7.57 Hz), 1.26 (3H, t, J = 7.67 Hz). 13C NMR (125 MHz, CDCl3): d 
150.8, 142.6, 140.5, 131.5, 128.9, 120.4, 52.8, 29.2, 24.5, 21.8, 15.6, 14.8.  
 
Enzyme synthesized (3) 1H NMR (600 MHz, CDCl3): d 7.13 (1H, s), 6.98 (1H, s), 
4.69 (1H, m), 4.56 (1H, br) 3.00 (2H, q, J = 7.64 Hz), 2.71 (2H, q, J = 7.65 Hz), 1.59 (3H, 
t, J = 6.68 Hz), 1.35 (3H, t, J = 7.56 Hz), 1.26 (3H, t, J = 7.61 Hz); 13C NMR (125 MHz, 
CDCl3): 150.8, 142.6, 140.4, 131.5, 128.8, 120.4, 52.8, 29.2, 24.5, 21.8, 15.6, 14.8.   
 
2,4,6-triethylbenzenesulfonamide (2) was synthesized by sodium borohydride 
reduction of 1.  1H NMR (500 MHz, CDCl3): d 7.01 (2H, s), 4.80 (br), 3.07 (4H, q, J = 7.25 
Hz), 2.63 (2H, q, J = 7.66 Hz), 1.29 (6H, t, J = 7.43 Hz), 1.24 (3H, t, J = 7.76); 13C NMR 
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(125 MHz, CDCl3): d 148.7, 144.8, 135.5, 129.4, 28.6, 28.5, 16.9, 15.2. Expected m/z for 
C12H19NO2S+ 241.1136, found 241.1146.  
 
2,4,6-trimethylbenzenesulfonyl azide (4) 1H NMR (500 MHz, CDCl3): d 7.02 
(2H, s), 2.66 (6H, s), 2.34 (3H, s); 13C NMR (125 MHz, CDCl3): d 144.7, 140.1, 133.4, 
132.3, 22.9, 21.3.   
 
(5) 1H NMR (500 MHz, CDCl3): d 7.06 (1H, s), 6.96 (1H, s), 4.73 (1H, br), 4.43 
(2H, d, J = 5.41), 2.59 (3H, s), 2.39 (3H, s); 13C NMR (125 MHz, CDCl3): d 144.3, 137.4, 
134.2, 131.7, 131.5, 122.4, 45.2, 21.7, 17.0.   
 
(7) 1H NMR (500 MHz, CDCl3): d 7.22 (1H, d, J = 1.11 Hz), 6.98 (1H, d, J = 1.32 
Hz), 4.45 (br, 1H), 3.61 (1H, sep, J = 6.85 Hz), 2.98 (1H, sep, J = 6.88 Hz), 1.63 (6H, s), 
1.35 (6H, d, J = 6.90), 1.27 (6H, d, J = 6.92); 13C NMR (125 MHz, CDCl3): d 155.7, 146.8, 
145.5, 131.0, 124.5, 117.9, 59.9, 34.8, 30.0, 29.6, 24.0, 23.7.   
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5. Assignment of absolute configuration.  
Absolute configuration of triethylsultam 3 was assigned by comparison to other 
compounds described in the literature.21 In particular, sultam 3 and monoethyl derivative 8 
(shown below) were previously synthesized in enantiopure form using a BINOL-iridium 
catalyst, which preferentially synthesized both (-)-3 αD20 -21.3 (c =1.01, CHCl3) and (-)-8 
[αD24] -26.9 (c = 1.00, CHCl3).21b The absolute configuration of 8, and the optical rotation 
values for its enantiomers have been previously reported (R)-8 [αD20] +31.0 (c = 0.6, 
CHCl3) and (S)-8 [αD20] -30 (c = 1.21, CHCl3).21a By analogy, the absolute configuration of 
the previously reported (-)-3 can be assigned as (S).  Preparative chiral HPLC to separate 
the enantiomers of the racemic standard of 3 allowed isolation of the earlier-eluting 
enantiomer (which was the enzymatically preferred product).  Measurement of the optical 
rotation of this material [aD25] -20.7 (c = 1.1, CHCl3) revealed it to be (S)-3. 
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C h a p t e r  3  
ENANTIOSELECTIVE IMIDATION OF SULFIDES VIA ENZYME-CATALYZED 
INTERMOLECULAR NITROGEN-ATOM TRANSFER 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as C. C. Farwell, J. A. McIntosh, T. K. Hyster, Z. J. Wang, F. H. 
Arnold  “Enantioselective Imidation of Sulfides via Enzyme-Catalyzed Intermolecular 
Nitrogen-Atom Transfer.” in Journal of the American Chemical Society. 2014, 136, 8766-
8771.  I conducted all enzyme reactions and characterization, including protein purification, 
reaction set up, product quantification and determination of enantioselectivity. J.A.M. 
synthesized product standards and assisted in conception of enzymatic sulfmidation. 
T.K.H. performed initial rate experiments. Myself and Z.J.W. performed UV/Vis analysis 
of the enzyme oxidation state. 
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Abstract 
Engineered enzymes with novel reaction modes promise to expand the application of 
biocatalysis in chemical synthesis and will enhance our understanding of how enzymes 
acquire new functions. The insertion of nitrogen-containing functional groups into 
unactivated C–H bonds is not catalyzed by known enzymes but was recently 
demonstrated using engineered variants of cytochrome P450BM3 (CYP102A1) from 
Bacillus megaterium.  Here, we extend this novel P450-catalyzed reaction to include 
intermolecular insertion of nitrogen into thioethers to form sulfimides.  An examination 
of the reactivity of different P450BM3 variants towards a range of substrates demonstrates 
that electronic properties of the substrates are important in this novel enzyme-catalyzed 
reaction.  Moreover, amino acid substitutions have a large effect on the rate and 
stereoselectivity of sulfimidation, demonstrating that the protein plays a key role in 
determining reactivity and selectivity.  These results provide a stepping-stone for 
engineering more complex nitrogen-atom transfer reactions in P450 enzymes and 
developing a more comprehensive biocatalytic repertoire.      
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Introduction   
Direct oxidation of unactivated C–H bonds and heteroatoms in small molecules is 
a valuable method for introducing complexity into industrially and medically important 
compounds.1  Modification of sulfur heteroatoms is particularly interesting given the 
potential for chirality in trivalent sulfur compounds and the efficacy of chiral sulfoxide 
therapeutics.2 Enzymes catalyze a wide range of reactions in nature, and oxygenases in 
particular are powerful catalysts of heteroatom oxidation and C–H bond activation.3  
Enzymes capable of catalyzing sulfoxidation are well documented4 and have even found 
industrial application,5 underscoring the utility of biocatalysis in heteroatom 
functionalization. 
The nitrogen analogs of sulfoxides, known as sulfimides (Figure 1), are useful 
building blocks in chemical synthesis,6 ligands for metal catalysts,7 and are functional 
groups in agrochemicals.8  Subsequent oxidation to form sulfoximines can be achieved 
with good chirality transfer,9 and the resulting compounds are a promising source of 
novel derivatives of therapeutic small molecules.10 Furthermore, sulfides substituted at 
the sulfur position with allyl groups can undergo a 2,3-sigmatropic rearrangement upon 
sulfimidation, resulting in formation of a new C–N bond.11a Available methods for 
producing sulfimides are largely based on organometallic catalytic systems using iron or 
rhodium, with only one example of an iron-based asymmetric sulfimidation catalyst 
reported.9,11 These methodologies typically require iminoiodinane nitrene precursors and 
chiral ligand frameworks to achieve stereoselectivity. Transition metal catalysts for 
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nitrenoid transfer also require high catalyst loadings and anhydrous conditions, and 
may also require high temperatures.12 
 
Figure 1. (A) P450-catalyzed sulfoxidation, shown proceeding through compound I.  
This reaction can also be mediated by compound 0 (hydroperoxy intermediate).  (B) 
Serine-ligated P411-catalyzed sulfimidation (this work), believed to proceed through a 
nitrenoid intermediate formed from an azide with N2 as a byproduct. 
 
Enzymes offer a “green” alternative to transition metal catalysts: they are regio- 
and stereoselective, non-toxic, function in aqueous media, and can be produced with ease 
in a suitable host organism. Whereas enzymatic sulfoxidation catalysts are well-known, 
enzymes that catalyze the analogous sulfimidation reaction have not been reported.  Our 
laboratory has recently shown that enzymes of the iron porphyrin-containing cytochrome 
P450 family can catalyze carbenoid and nitrenoid insertion reactions with high activity 
and selectivity.13 Mutations to conserved residues T268 and C400 in P450BM3 from 
Bacillus megaterium were found to dramatically enhance reactivity for non-natural 
chemistry.  The C400S mutation, which replaces the axial cysteine with serine, was 
particularly activating toward C–H amination and toward olefin cyclopropanation in 
whole cells.13b,c The resulting shift in the ferrous-CO Soret band from 450 nm to 411 nm 
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prompted the ‘P411’ description for P450BM3 variants having the C400S mutation 
(Figure 1).  These ‘chemo-mimetic’ enzyme systems offer several advantages over 
transition metal complexes. Because they are genetically encoded, tuning of selectivity 
and reactivity can be achieved through directed evolution.  Moreover, these novel 
enzyme catalysts operate under mild, aqueous conditions amenable to sustainable 
chemical synthesis.  
Previously, we and Fasan have shown that variants of P450BM3 catalyzed the 
intramolecular C–H amination of arylsulfonylazides with high selectivities and hundreds 
of total turnovers.13c,14 To further develop enzymatic nitrene transfer, we wished to 
explore intermolecular reactions, given the clear synthetic applications in building 
complexity in a convergent manner.  Additionally, we reasoned that an intermolecular 
nitrene transfer reaction would allow a more detailed mechanistic characterization than 
was possible with the intramolecular reaction.  Given that variants of P450BM3 are 
promising enantioselective sulfoxidation and C–H amination catalysts, we sought to 
determine whether P450 variants could catalyze the nitrogen analog of sulfoxidation, the 
intermolecular insertion of nitrogen into organosulfur compounds.  This study describes 
the first report of intermolecular nitrene transfer catalyzed by an enzyme, in the context 
of imidation of organosulfur compounds.  
 
Results and Discussion 
In our previous work on intramolecular C–H amination, we were limited to aryl 
sulfonylazide substrates as nitrene precursors.  Despite the success with this substrate 
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class, we wished to assess the influence of the R-group on the nitrenoid transfer, and 
thus tested a series of substrates displaying a range of stereo-electronic properties that 
have been shown to be effective nitrene precursors in other contexts (Figure S1, 1–
6).11b,12 
For the thioether acceptor substrate we chose thioanisole, which has been used in 
enzymatic sulfoxidation by cytochrome P450s and other oxygenase enzymes.4b,4d As a 
catalyst, we used the P411BM3-CIS T438S variant of cytochrome P450BM3, possessing the 
aforementioned C400S mutation. This enzyme, which contains 14 mutations relative to 
wild-type P450BM3 (Table S1), was previously shown to be a good catalyst in the 
activation of azides for intramolecular C–H insertion.13c Reaction conditions were similar 
to those reported previously for intramolecular C–H amination13c under anaerobic 
conditions with NADPH supplied as a reductant.   
Considering the small size of reactive oxygen species naturally produced by 
P450s, we anticipated that smaller azides, such as mesyl azide (4), would be less 
sterically demanding than aryl or arylsulfonyl azides and thus a more suitable partner for 
reaction with thioanisole.  We were therefore surprised to find that of all the azides 
initially examined, sulfimidation activity was only observed with tosyl azide (1) as the 
nitrene source (30 total turnovers, TTN, Figure S1).  Control experiments confirmed that 
enzyme was necessary for sulfimide formation (Table S2). Free hemin showed no activity 
in this transformation. As we reported previously for intramolecular C–H amination, 
some of the azide was reduced to sulfonamide, in this case p-toluenesulfonamide (9).13c    
  
51 
In other non-natural P450 reactions reported to date, it was shown that amino 
acid substitutions could alter both the activity and stereoselectivity of the enzymes.13a,c  
Thus we tested how the mutation of conserved residues C400 and T268 and other active-
site residues affects sulfimidation activity (Table 1).  For these experiments we used the 
more reactive sulfide 4-methoxythioanisole, for which we measured 300 TTN with 
P411BM3-CIS T438S (see below for more discussion of the effect of sulfide substituents 
on reactivity). 
Since activating mutations T268A and C400S were already present in P411BM3-
CIS T438S, we tested the effects of reverting each mutation to the wild-type residue 
(Table 1, entries 1-3).  Each revertant was much less active than the parent, supporting 
the benefit of having the C400S and T268A mutations for effective nitrene-transfer 
chemistry.  Given the bulky nature of the aryl sulfonylazide nitrene sources and aryl 
thioethers, we next tested the C400S mutants of several P450BM3 variants that had been 
engineered via combinatorial alanine scanning to hydroxylate large substrates15 (Table 1, 
Entries 4-6). While P411BM3-H2-5-F10 displayed comparably high levels of activity to 
P411BM3-CIS (>100 TTN), the other mutants we tested from this library were less 
productive.   We also tested the effects of introducing the activating mutations into wild-
type P450BM3.  Although these wild-type derivatives were highly active and 
stereoselective for intramolecular C–H amination,13c here we found that neither the single 
mutant (T268A or C400S) nor the double mutant (T268A + C400S) are particularly 
active for intermolecular sulfimidation. 
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Table 1. Sulfimidation activity and selectivity of P450BM3 variants using substrates 
and reaction conditions shown 
 
a “P411” denotes Ser-ligated (C400S) variant of cytochrome P450BM3. Variant IDs and 
specific amino acid substitutions in each can be found in Table S1.  TTN = total turnover 
number, e.r. = enantiomeric ratio, nd = not determined.   
 
The turnover data presented above demonstrate the sequence dependence of 
sulfimidation productivity. The effects, however, could be due to changes in stability of 
the enzymes that lead to degradation over the course of the reaction.  To address this 
possibility, we compared the initial rates of reaction using the most productive enzyme in 
MeO
S
Me
Me
S
N3
O O
MeO
S
Me+
N
Ts
Enzyme
0.2 mol %
0.1 M KPi
pH= 8.0
RT, 4 hours7a 1 8a
Entry Enzymea TTN e.r. 
1 P411BM3-CIS-T438S 300 74:26 
2 P450BM3-CIS-T438S 7 nd 
3 P411BM3-CIS-A268T-T438S 19 nd 
4 P411BM3-H2-5-F10 140 29:71 
5 P411BM3-H2-A-10 84 57:43 
6 P411BM3-H2-4-D4 32 70:30 
7 P450BM3 10 nd 
8 P411BM3 11 nd 
9 P450BM3-T268A 19 nd 
10 P411BM3-T268A 17 nd 
11 P411BM3-CIS-I263A-T438S 320 18:82 
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terms of total turnover, P411BM3-CIS-T438S, and the less productive P411BM3-H2-A-10 
and P411BM3-H2-4-D4 enzymes (Figure S2).  Differences in the total productivity (i.e., 
TTN) for each enzyme are mirrored in the initial rates of reaction (Table S4), suggesting 
that specific amino acids proximal to the heme influence binding and orientation of the 
substrates to effect catalytic rate enhancement.   
The key role of active site architecture in guiding reaction trajectory is further 
supported by the effects of amino acid substitutions on the reaction stereochemistry.  
Indeed, we found enzymes capable of producing an excess of either sulfimide 
enantiomer: e.g., P411BM3-CIS-T438S gives an e.r. of 74:26, while expanded active site 
variant P411BM3-H2-5-F10 exhibited the opposite selectivity, giving 29:71 (Figure S4).  
Among the H2-mutants (which differ from P411BM3-CIS-T438S by 3-5 amino acid 
substitutions, Table S1), H2-5-F10 was alone in containing the I263A mutation, 
suggesting that this mutation is responsible for the enantiomeric inversion observed in the 
P411BM3-H2-5-F10 variant.  When the I263A mutation was placed in the P411BM3-CIS-
T438S background, an even more pronounced inversion in selectivity was observed (e.r. 
= 18:82 for the P411BM3CIS-I263A-T438S, compared to 74:26 for P411BM3CIS-T438S).  
This enzymatic system not only induces asymmetry in sulfimide products, it also 
provides tunability in which selectivity can be switched with just a few mutations.  
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Table 2. Impact of sulfide substituents on sulfimidation activity 
 
* Trace product observed by LC-MS. 
Previous studies of P450-catalyzed sulfoxidation16 as well as rhodium-catalyzed 
C–H amination17 suggest that the electronic properties of sulfide or alkyl acceptor 
substrates significantly impact reactivity.  Thus, to better understand the mechanism of 
this new enzyme reaction, we sought to establish how thioether electronic properties 
affected enzyme-catalyzed sulfimidation.  We chose a set of aryl sulfide substrates with 
substituents encompassing a range of electronic properties, from strongly donating to 
weakly withdrawing.  As a first approximation of the effect of sulfide electronics, we 
examined the total number of turnovers catalyzed by P411BM3-CIS-T438S in the reactions 
of different sulfides with tosyl azide (Table 2).  In general, sulfides containing electron-
donating substituents on the aryl sulfide ring were better substrates for sulfimidation.  For 
example, the enzyme reaction containing 4-methoxythioanisole (7a) gave the highest 
S Me
P411BM3-CIS T438S
(0.2 mol %)
5% DMSO
0.1 M KPi (pH=8.0)
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Entry R1 in 7 R2 in 7 TTN 8 TTN 9 
a -OMe -H 300 270 
b -Me -H 190 400 
c -H -Me 100 390 
d -H -H 30 500 
e -CHO -H < 1* 510 
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levels of activity (300 TTN).  In contrast, the electron-deficient p-aldehyde substrate 
(7e) gave only trace amounts of sulfimide product.  Further, some azides that initially 
appeared entirely inactive gave small amounts of sulfimide products when reacted with 4-
methoxythioanisole, underscoring the importance of sulfide electronics in this reaction 
(Table S3).  The identity of substrates also exerted a modest influence on the 
enantioselectivity of sulfimidation.  In particular, P411BM3-CIS-T438S gave e.r. values for 
substrates 8a-8d that ranged from 59:41 for 8c to 87:13 for 8d (Table S5, Figures S4-S7).  
While it is possible that some sulfides were poorer substrates due to the steric influence 
of the para substituent, the overall trend is strongly suggestive of electron induction to 
the aryl sulfide being a major contributor to activity. One notable aspect of these 
reactions is that significantly more sulfonamide (9) was produced when less reactive 
sulfides were used. 
Although the total turnover data suggest that sulfide electronics influence 
reactivity, this result could also be due to other factors, such as substrate-dependent 
enzyme inactivation.  To assess the effect of sulfide substituents on reactivity more 
directly, we measured the initial rates of reaction of tosyl azide with the sulfides 7a-7d in 
Table 2.  The initial rates correlated well with the total turnover data presented above, 
with p-OMe showing the highest rate of reaction (Figure S3).  Given this correlation, we 
sought to obtain more mechanistic information by fitting the data to a Hammett plot that 
correlates the observed rates with each substituent’s Hammett parameter.18  We found a 
strong, linear relationship with a Hammett value of ρ = -4.0 (Figure 2), which suggests 
that during the rate-limiting step there is a buildup of positive charge on the sulfide that is 
  
56 
stabilized by electron-donating substituents.  This observation is consistent with 
Hammett values obtained for the oxidation of thioanisoles in P450-catalyzed 
sulfoxidation reactions, though the magnitude of ρ for sulfimidation is significantly 
greater than for sulfoxidation (-4.0 versus -0.2).16 One possible explanation for this 
difference is that the presumed nitrenoid intermediate of this reaction (Figure 1) is a 
weaker oxidant than compound I, making the nucleophilicity of sulfur an important 
contributor to the rate of nitrenoid transfer.  The large difference in the magnitude of ρ 
could also indicate a change in mechanism relative to P450 sulfoxidation: whereas 
Watanabe and coworkers have proposed that sulfoxidation proceeds through a single 
electron transfer process,16 sulfimidation may occur via direct nucleophilic attack of the 
thioether on the nitrenoid intermediate.  
 
Figure 2.  Plot of reaction rate versus Hammett parameter of substituted aryl sulfides 
using the P411BM3-CIS-T438S enzyme and tosyl azide nitrogen source.  Data points are 
labeled with aryl substituent and position (p- = para, m- = meta) and Hammett parameters 
obtained from Hansch et al.18 
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As noted above, we observed that a greater proportion of sulfonamide side 
product was formed when less reactive sulfides were used. The varying amounts of this 
side-product prompted us to examine more closely how sulfonamide might be produced.  
We first tested the possibility that azide is reduced by some additive in the reactions (i.e., 
glucose oxidase, catalase, NADPH, etc.) by simply omitting the P450 enzyme from the 
reactions (Table S2).  We found that no-enzyme controls yielded very little reduced 
sulfonamide product (more than 10-fold lower than with enzyme present).  While these 
experiments showed that enzyme was likely involved in azide reduction, this still left 
several possibilities. Since P411BM3’s heme domain is fused to a reductase, we considered 
the possibility that azide reduction occurs via direct hydride transfer from the reductase, 
as has been observed for aldehyde reductions.19 We used carbon monoxide-inhibited 
reactions to investigate this possibility, since CO binding to the heme iron should have no 
effect on the reductase domain.  In the presence of CO, we observed a significant 
decrease in the sulfonamide produced, suggesting that azide reduction occurs at the heme.  
Furthermore, only trace sulfonamide was observed when reactions were conducted in the 
presence of oxygen, further supporting the involvement of reduced heme in azide 
reduction. Since all the available evidence suggests that azide reduction and sulfimide 
formation both occur at the heme, the most parsimonious explanation is that both 
reactions stem from a common intermediate that can give rise to both sulfonamide and 
sulfimide products.  
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We propose a mechanism of sulfonamide and sulfimide formation that begins with 
the iron (III) heme gaining an electron from NADPH via the flavin cofactors of the 
reductase domain (Figure 3). Addition of azide substrate results in the formation of a 
formal iron (IV) nitrenoid, which can either be reduced by subsequent electron transfer or 
‘trapped’ by sulfide to form sulfimide product. We hypothesize that a second electron 
transfer followed by protonation of the nitrenoid to generate sulfonamide restores the 
heme iron to its ferric state, and additional reductant is required to return to the 
catalytically active ferrous state (Figure 3, unproductive pathway).   
 
Figure 3.  Proposed mechanisms of sulfimide (‘productive’) and sulfonamide 
(‘unproductive’) formation.  
 
To test whether ferric heme is involved in the unproductive pathway, we 
monitored the change in the visible absorbance spectrum of the reduced holoenzyme 
P411BM3-CIS-I263A-T438S upon addition of NADPH followed by azide.  The Ser-
ligated P411 proteins exhibit different absorbance properties in the ferric and ferrous 
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states compared with their Cys-ligated counterparts, such that the ferric, ferrous, and 
CO-ferrous Soret bands are shifted from 418, 408, and 450 nm to 405, 422, and 411 nm, 
respectively (Figure S8).13b  When NADPH was added to a solution of enzyme under an 
anaerobic atmosphere, we observed reduction of the heme from the ferric to the ferrous 
state.  When a degassed solution of azide was added to the ferrous protein, we observed 
an immediate shift back to the ferric state, with concomitant production of sulfonamide, 
verified by HPLC.  This observation suggests that the unproductive azide reduction 
pathway occurs readily in the absence of sulfide and that, when provided only with azide, 
the catalyst rests in the ferric state.   
To determine the resting state of the P411 catalyst in sulfimidation, we repeated 
the above experiment in the presence of both sulfide and azide.  Addition of sulfide to a 
solution of enzyme and NADPH results in no change in the Q or Soret bands, with the 
iron heme remaining in the ferrous state.  However, addition of azide to this solution 
causes the iron heme to shift to the ferric state.  After 10 min, peaks corresponding to the 
ferrous heme begin to grow until the ferrous heme becomes the dominant species at 30 
min (Figure S9).  Both sulfonamide and sulfimide products are formed throughout the 
course of the reaction. Our observations are consistent with the competing reaction 
pathways outlined in Figure 3 and suggest that the catalyst rests as a mixture of ferric and 
ferrous hemes during sulfimidation.  When the concentration of azide is high, as it is at 
the beginning of the reaction, the unproductive pathway is favored and a ferric resting 
state dominates.  As azide is consumed, both the ferric and ferrous resting states can be 
observed.   
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P450 monooxygenases are known to undergo an ‘oxidase uncoupling’ side 
reaction in which compound I is reduced by two electrons to give water, which bears 
some similarity to the process of azide reduction we have observed here.  One difference, 
however, is that only a single electron transfer is required to attain a reactive state in 
nitrene-transfer chemistry.  This stands in contrast to P450 monooxygenase chemistry, 
where the generation of compound I from O2 requires the transfer of two electrons.  Thus, 
one explanation for the relatively high proportion of reduced azide in these reactions is 
that the electron-transfer machinery in P450BM3 is evolved to carry out two-electron 
reductions.20  In the case of nitrene-transfer chemistry, reducing the ferric heme to the +2 
state allows nitrenoid formation, but a second electron transfer would generate an 
unreactive iron(III)-sulfonamide complex.  Coupled with the fact that lower sulfide 
concentrations and less-reactive sulfides lead to increased azide reduction, these 
observations are consistent with the mechanism discussed above in which sulfimide 
formation competes with azide reduction.  Since electron transfers from the reductase 
domain are quite rapid,21,13b only relatively reactive sulfides can successfully compete 
with reduction to form sulfimide.   
The mechanistic picture described above suggests that achieving higher levels of 
sulfide occupancy in the active site should favor sulfimide formation and inhibit azide 
reduction. This could be achieved with tighter binding of the sulfide acceptor substrate or 
by increasing the concentration of sulfide relative to azide. We therefore tested whether 
excess sulfide or slow addition of azide would increase sulfimide formation relative to 
sulfonamide. Increasing the sulfide concentration decreased reduction of azide to 
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sulfonamide and improved the ratio of sulfimide to sulfonamide, from 0.6 (with 0.5 eq 
sulfide) to 1.8 (with 4 eq sulfide) (Figure S10, Table S6). Slow azide addition slightly 
increased the TTN for sulfimide and decreased sulfonamide formation in a two-hour 
reaction (Figure S11).  That higher concentrations of sulfide substrate improve sulfimide 
production suggests that protein engineering to improve the binding of sulfide acceptor 
substrates could also produce strong gains in the desired activity.  Indeed, the specific 
activities of the enzyme catalysts reported here compare favorably with enantioselective 
iron-based catalysts, which routinely require catalyst loadings of 10 mol %.9b 
Furthermore, engineering the holoenzyme or reductase domain to favor one-electron 
transfers might improve the proportion of desired product relative to azide reduction, 
which could allow reaction with more challenging organic acceptor substrates.  
  
Conclusions 
 This is the first report of intermolecular nitrene transfer catalyzed by an enzyme, 
allowing for a mechanistic analysis of this new enzyme activity. Similar to P450-
catalyzed sulfoxidation, we find that the electronic properties of the sulfide substrates 
strongly influence reactivity, though the magnitude of the substituent effects is greater for 
nitrene transfer, possibly owing to the less oxidizing nature of the presumed nitrenoid 
intermediate as compared to compound I.  The necessity of the C400S mutation for 
sulfimidation can be rationalized along similar lines: the less electron-donating axial 
serine ligand in P411 enzymes likely makes the nitrenoid species a more potent oxidant.  
The impact of sulfide substituents on sulfimide formation is also reflected in the 
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generation of sulfonamide side product, suggesting that the nitrenoid undergoes rapid 
reduction and can only productively insert into sufficiently reactive sulfides.  
Characterization of the redox state of the heme iron in the presence and absence of 
nitrene source and sulfide acceptor supports the proposal that nitrenoid ‘over-reduction’ 
competes with productive sulfimide formation and that the former is a two-electron 
process resulting in regeneration of ferric heme.   Another interesting aspect of this 
enzyme reaction is the strong preference for an aryl sulfonylazide nitrene source: 
although monooxygenation reactions use a small donor substrate (dioxygen), only trace 
sulfimidation was observed with small azides such as ethanesulfonyl azide (Table S3).  
The ability of the enzyme to accept larger aryl substrates may be beneficial for 
development of enantioselective intermolecular nitrene-transfer catalysts, as we have 
observed that a single mutation can dramatically affect the enantioselectivity of reaction. 
Intermolecular nitrene transfer in the form of sulfimidation can now be added to the 
impressive array of natural and non-natural chemistry catalyzed by cytochrome P450 
enzymes.     
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1. Materials and Methods 
General. Unless otherwise noted, all chemicals and reagents for chemical reactions were 
obtained from commercial suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used 
without further purification.  Silica gel chromatography purifications were carried out 
using AMD Silica Gel 60, 230-400 mesh.  1H spectra were recorded on a Varian Inova 
500 MHz instrument in CDCl3, and are referenced to the residual solvent peak. Synthetic 
reactions were monitored using thin layer chromatography (Merck 60 gel plates) using an 
UV-lamp for visualization.  
Chromatography. Analytical high-performance liquid chromatography (HPLC) was 
carried out using an Agilent 1200 series, and a Kromasil 100 C18 column (Peeke 
Scientific, 4.6 x 50 mm, 5 µm). Semi-preparative HPLC was performed using an Agilent 
XDB-C18 (9.4 x 250 mm, 5 µm).  Analytical chiral HPLC was conducted using a 
supercritical fluid chromatography (SFC) system with isopropanol and liquid CO2 as the 
mobile phase.  Chiralcel OB-H and OJ columns were used to separate sulfimide 
enantiomers (4.6 x 150 mm, 5 µM). Sulfides were all commercially available and 
sulfimide standards were prepared as reported.1  e.r. values were determined by dividing 
the major peak area by the sum of the peak areas determined by SFC chromatography.   
Cloning and site-directed mutagenesis. pET22b(+) was used as a cloning and 
expression vector for all enzymes described in this study.  Site-directed mutagenesis on 
P411BM3-CIS-T438S to generate P411BM3-CIS-I263A-T438S was performed using a 
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modified QuickChangeTM mutagenesis protocol.  The PCR products were gel purified, 
digested with DpnI, and directly transformed into E. coli strain BL21 (DE3).   
Table S1. Mutations present in P450BM3 variants used in this work. 
Enzyme Mutations relative to wild-type P450BM3 
P450BM3 none 
P450BM3-T268A T268A 
P411BM3 C400S 
P411BM3-T268A T268A, C400S 
P450BM3-CIS-T438S V78A, F87V, P142S, T175I, A184V, S226R, 
H236Q, E252G, A290V, L353V, I366V, T438S, 
E442K 
P411BM3-CIS-T438S P450BM3-CIS C400S, T438S 
P411BM3-CIS-A268T-
T438S 
P450BM3-CIS, A268T, C400S, T438S 
P411BM3 H2-A-10 P450BM3-CIS, L75A, L181A, C400S, 
P411BM3 H2-5-F10 P450BM3-CIS, L75A, I263A, C400S, L437A 
P411BM3 H2-4-D4 P450BM3-CIS, L75A, M177A, L181A, C400S, 
L437A, T438S  
 
Determination of P450 concentration.  Concentration of P450/P411 enzymes was 
accomplished by quantifying the amount of free hemin present in purified protein using 
the pyridine/hemochrome assay.22 
Protein expression and purification.  Enzymes used in purified protein experiments 
were expressed in BL21(DE3) E. coli cultures transformed with plasmid encoding P450 
or P411 variants.  Expression and purification was performed as described elsewhere,3 
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except that the shake rate was lowered to 130 RPM during expression.  Following 
expression, cells were pelleted and frozen at -20 °C. For purification, frozen cells were 
resuspended in buffer A (20 mM tris, 20 mM imidazole, 100 mM NaCl, pH 7.5, 4 mL/g 
of cell wet weight) and disrupted by sonication (2 x 1 min, output control 5, 50% duty 
cycle; Sonicator 3000, Misonix, Inc.). To pellet insoluble material, lysates were 
centrifuged at 24,000 x g for 0.5 h at 4 °C.  Proteins were expressed in a construct 
containing a 6x-His tag and were consequently purified using a nickel NTA column (5 
mL HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTAxpress purifier FPLC 
system (GE healthcare).  P450 or P411 enzymes were then eluted on a linear gradient 
from 100% buffer A 0% buffer B (20 mM tris, 300 mM imidazole, 100 mM NaCl, pH 
7.5) to 100 % buffer B over 10 column volumes (P450/P411 enzymes elute at around 80 
mM imidazole).  Fractions containing P450 or P411 enzymes were pooled, concentrated, 
and subjected to three exchanges of phosphate buffer (0.1 M KPi pH 8.0) to remove 
excess salt and imidazole.  Concentrated proteins were aliquoted, flash-frozen on 
powdered dry ice, and stored at -20 °C until later use.   
2. Confirmation of enzyme activity 
Controls to confirm the enzymatic sulfimidation activity of variant P411BM3CIS 
T438S.  Small-scale reactions (400 µL total volume) were set up and worked up as 
described above.  For the reaction containing hemin as catalyst, 10 µL of a hemin 
solution (1 mM in 50% DMSO-H2O) was added to a final concentration of 25 µM.  TTNs 
were determined as described above and are presented in Table S2.  CS denotes a 
‘complete system’ in which all components of the reactions as described above are 
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present.  Variations from the complete system are denoted with a “- X”, where X is the 
component removed. 
Table S2. Control experiments using substrate 7c yielding products 8c (sulfimide) and 9 
(sulfonamide).  CS = complete system.  
Condition TTN 8c TTN 9 
P411BM3-CIS T438S (CS) 90 300 
CS - NADPH 1 2 
CS + Na2S2O4 + CO 2 40 
CS boiled enzyme 1 53 
CS aerobic 2.3 16 
Hemin + Na2S2O4 0 42 
CS - P411BM3-CIS T438S 0 21 
 
3. Reaction Development and Conditions 
Typical procedure for small-scale sulfimidation bioconversions under anaerobic 
conditions using purified enzymes. Small-scale reactions (400 µL) were conducted 
anaerobically in 2 mL crimp vials as described in Chapter 2.13c A solution of aryl sulfide 
in DMSO or methanol (100 mM, 10 µL) was added to the reaction vial via syringe, 
followed by arylsulfonyl azide (100 mM, 10 µL, DMSO).  Final concentrations of the 
reagents were typically: 2.5 mM aryl sulfide, 2.5 mM arylsulfonyl azide, 10 mM 
NADPH, 25 mM glucose, 5-20 µM P450. To the vials were then added acetonitrile (460 
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µL) and internal standard (1,3,5 trimethoxybenzene, 10 mM in 10% DMSO/90% 
acetonitrile, 1 mM final concentration).  This mixture was then transferred to a 
microcentrifuge tube, and centrifuged at 17,000 x g for 5 minutes.  A portion (20 µL) of 
the supernatant was then analyzed by HPLC. Sulfimide formation was quantified by 
comparison of integrated peak areas of internal standard (1,3,5-trimethoxy benzene, 1 
mM or 1,3,5-trichlorobenzene, 1 mM) and sulfimide at 220 nm to a calibration curve 
made using synthetically produced sulfimide and internal standard.  Coefficients 
determined from standard curves were multiplied by a dilution factor in order to obtain 
sulfimide concentrations in the reaction mixture. For chiral HPLC, the quenched reaction 
mixture was extracted twice with ethyl acetate (2 x 350 µL), dried under a light argon 
stream, and resuspended in acetonitrile (100 µL). 
 
Figure S1. Azides tested as nitrene sources for sulfimidation of thioanisole using the 
P411BM3-CIS T438S enzyme. TTN = total turnover number. 
 
 
 
S N3
O O
S N3
O O
S N3
O O
O N3
O
Cl3C
F3C
MeO
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N3
1 2 3
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30 TTN no reaction no reaction
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Table S3. Qualitative description of reaction productivity using para-methoxy aryl 
sulfide 7a and azides shown in Figure S1. 
 
Azide Productivity a 
    1          +++ 
    2          + 
    3         nd b 
    5          + 
    6         nd 
a + denotes relative amount of product, where +++ is the most productive reaction.  See 
Figures S26 and S27 for LC-MS verification of product formation for azides 2 and 4. b nd 
= none detected.   
 
 
4. Determination of Reaction Rates 
Initial rates.  Four 2-ml vials were charged with a stir bar, 10x oxygen depletion 
system13c (40 µL), and a solution of enzyme prior to crimp sealing with a silicon septum. 
Once sealed, the headspace was flushed with argon for at least 10 minutes. Concurrently, 
a sealed 6-mL vial charged with glucose (250 mM, 400 µL), NADPH (20 mM, 400 µL), 
and KPi (pH = 8.0, 0.1 M, 2.6 mL) was sparged for 10 minutes with argon. After 
degassing was complete, 340 µL of the reaction solution was transferred to the 2-mL vial 
via syringe. Sulfide (100 mM, 10 µL) was added to all four 2-mL vials followed quickly 
(less than 20 seconds) by tosyl azide (100 mM, 10 µL). The reactions were quenched at 
1-2 minute intervals over 5-10 minutes by decapping and adding acetonitrile (460 µL). 
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After 5 minutes of stirring, the vials were charged with internal standard and the 
reaction mixtures were transferred to 1.8 mL tubes, which were vortexed and centrifuged 
(14,000 x g, 5 min). The supernatant was transferred to a vial for analysis by HPLC.  
Initial rates are plotted for individual enzymes referenced in the text in Figure S2, and for 
various substituted aryl sulfides in Figure S7.  
 
Figure S2. Data used to determine initial rates of the reaction depicted in the scheme 
above using the enzymes listed in the figure legend. 
 
 
 
 
 
MeO
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Table S4. Initial rates determined from data presented in Figure S2 and TTNs 
presented in Table 1. 
Enzyme Rate (nmol min-1) TTN 
P411BM3-CIS T438S 33  300 
P411BM3-H2-A-10 3.5 32 
P411BM3-H2-4-D4 5.9 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Data used to determine initial rates for reaction of substituted aryl sulfides 
with tosyl azide, using P411BM3-CIS T438S as catalyst.  Sulfimide products measured are 
as listed in Table 2 of the text.  
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5. Determination of Reaction Enantioselectivity 
Table S5.  Enantioselectivity of products 8a–8d with P411BM3-CIS T438S enzyme. 
 
 
 
Product e.r. R1 R2 
8a 74:26  -OMe -H 
8b 80:20 -Me -H 
8c 59:41 -H -Me 
8d 87:13 -H -H 
 
 
 
S
Me
P411BM3-CIS T438S
(0.2 mol %)
5% DMSO
0.1 M KPi (pH=8.0)
anaerobic, 4h, RT
7a-d
S
Me
8a-d
N
Ts
R1
R2
R1
R2
+
1
S
Me
N3O
O
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Figure S4.  A) SFC trace of synthetic standard of 8a using Chiralpak OD-H column with 
25% isopropanol/75% supercritical CO2 mobile phase.  B) Trace of P411BM3-CIS T438S 
produced 8a under same conditions as synthetic standard.  C) Trace of P411BM3-H2-5-
F10 produced 8a.  D) Trace of P411BM3-CIS-I263A-T438S produced 8a, using 20% 
isopropanol/80% supercritical CO2 mobile phase.   
 
 
 
A 
B 
C 
D 
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Figure S5.  Top: SFC trace of 8b synthetic standard using Chiralpak OD-H column with 
20% isopropanol/80% supercritical CO2 mobile phase.  Bottom: Trace of enzyme 
produced 8b. 
 
Figure S6 Top: SFC trace of 8c synthetic standard using Chiralpak OJ column with 15% 
isopropanol/85% supercritical CO2 mobile phase.  Bottom: Trace of enzyme produced 8c.   
 
Figure S7. Top: SFC trace of 8d synthetic standard using Chiralpak OJ column with 15% 
isopropanol/85% supercritical CO2 mobile phase.  Bottom: Trace of enzyme produced 
8d. 
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6.  Synthetic Procedures 
All sulfides presented in Table 2 were obtained from commercial sources (Sigma 
Aldrich, Alfa Aesar).  Sulfimide standards were synthesized as previously reported.11c  
8a 
 
1H NMR (500 MHz; CDCl3): δ = 7.71 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.9 Hz, 
2H), 7.15 (d, J = 8.35 Hz, 2H), 6.96 (d, J = 8.9 Hz, 2H), 3.83 (s, 3H), 2.81 (s, 3H), 2.34 
(s, 3H) 
8b 
	  
1H NMR (500 MHz; CDCl3): δ = 7.72 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 
2H), 7.28 (d, J = 7.3 Hz, 2H), 7.16 (d, J = 8.1 Hz, 2H), 2.82 (s, 3H), 2.39 (s, 3H), 2.35 (s, 
3H) 
8c 
 
 
1H NMR (500 MHz; CDCl3): δ = 7.73 (d, J = 8.0 Hz, 2H), 7.48-7.33 (m, 4H), 7.17 
(d, J = 8.1 Hz, 2H), 2.82 (s, 3H), 2.36 (s, 3H), 2.35 (s, 3H) 
 
 
S Me
NTs
MeO
Me
S Me
NTs
S Me
NTs
Me
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8d 
  
 
1H NMR (500 MHz; CDCl3): δ = 7.72 (d, J = 7.8 Hz, 2H),  7.55-7.46 (m, 5H), 7.16 (d, J 
= 8.1 Hz, 2H), 2.83 (s, 3H), 2.34 (s, 3H) 
The 1H NMR listings above for products 8a-8d matched those of characterized 
compounds.9b 
 
7. Observation of Catalytic Resting States.  
To a semi-micro anaerobic cuvette, 8 µL of P411BM3CIS I263A T438S (400 µM) was 
added.  To obtain a spectrum of the ferric protein, 0.5 mL of degassed phosphate buffer 
was added to the cuvette and the visible spectrum was recorded from 650 to 400 nm.  To 
obtain a spectrum of the ferrous protein, the cuvette was sealed with a cap equipped with 
rubber septa and the headspace of the cuvette was purged with a gentle stream of Ar for 3 
minutes.  A solution of NADPH (5 mM) was added to a 6 mL crimp vial and made 
anaerobic by sparging with Ar for 5 minutes.  The NADPH solution (0.5 mL) was then 
added to the anaerobic cuvette containing protein.  Visible spectra of the protein sample 
are recorded until a stable ferrous state is reached.  Representative spectra of the Fe(III)- 
and Fe(II)-protein are shown below (Figure S8 green and red lines, respectively).   
To determine the resting state of the protein in the unproductive catalytic cycle, a 
degassed solution of tosyl azide (2 µL, 400 mM in DMSO) was added to a fully reduced 
S Me
NTs
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sample of ferrous protein.  The visible spectrum of the protein shifted to the ferric 
heme immediately and remained unchanged for 20 minutes.  The addition of an aliquot of 
organic solvent of similar volume did not cause the observed change in the iron oxidation 
state.  At the end of 20 minutes (Figure S8, blue line), the cuvette was uncapped and the 
reaction mixture was worked up following the general procedure for small scale 
reactions.  HPLC of the resulting solution confirmed that a substantial amount of azide is 
reduced to the corresponding sulfonamide.    
To determine the resting state of the protein during the sulfimidation reaction, a 
degassed solution of sulfide 7a (2 µL, 400 mM in DMSO) was added to the cuvette 
containing P411BM3CIS I263A T438S in the presence of NADPH.  A visible absorbance 
spectrum of the mixture was recorded to ensure that the oxidation state of iron heme is 
unchanged.  Next, a degassed solution of tosyl azide (2 µL, 400 mM in DMSO) was 
added to the cuvette.  Visible absorbance spectra of the solution were recorded at 5, 7, 12, 
18, 22, 25, and 30 min (Figure S9).  The appearance of ferrous heme is observed over 
time.  HPLC confirmed formation of both sulfimide and sulfonamide.  
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Figure S8. Visible spectroscopy of Fe(III) (green) and Fe(II)-P411BM3CIS I263A T438S 
in the presence of NADPH (red), followed by azide addition (blue).   
 
 
Figure S9.  Monitoring the iron heme during the sulfimidation reaction with azide and 
sulfide.  As shown in Figure S8, the Soret peak for the Fe(III) state is obscured by 
NADPH.  Therefore the Q-band region (enlarged box from 530-640 nm) was used to 
assess the transition from Fe(III) to Fe(II) as the reaction proceeds as described in the 
supplemental text.    
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8.  Excess sulfide and azide slow addition experiments.  
To assess the impact of sulfide concentration on overall productivity of the reaction, 
sulfide was added to the reaction ranging from 0.5 eq to 4 eq relative to azide.  1 eq of 
azide denotes 1 mM in the small scale reactions described above.  Results are plotted in 
Figure S10 below as a ratio of the TTN for sulfimide vs. TTN for sulfonamide.  Slow 
addition was accomplished by adding 1 µL of a 100 mM (100 nmol) tosyl azide solution 
(DMSO) at 15 minute intervals to a reaction set up, as described previously, with 0.4% 
catalyst loading and containing 2.5 mM 7a.  Azide was added over 150 minutes until 
equimolar final concentrations of sulfide and azide were achieved.  Results of the slow 
addition are presented in Figure S11.  
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Figure S10. Ratio of sulfimide TTN to sulfonamide TTN as sulfide concentration is 
varied, using P411BM3-CIS T438S enzyme, as shown in the scheme.  Reactions were 
assembled as described above, with azide concentration held constant at 1 mM and 
sulfide concentration varied from 0.5 mM to 4 mM.  
 
 
 
 
 
 
 
 
 
 
S
MeO
SO2N3
Me
+
P411BM3-CIS (10 uM)
0.1 M KPi, pH = 8.0
RT, 4 hours
1 eq0.5 - 4 eq
S
NTs
MeO
+
Me
SO2NH2
7.1 8
 
    
P4 1BM3-CIS T438S (10 
8a 9 0.5 – 4 
eq 
1 eq 
  
81 
Table S6:  Production of sulfimide 8a and sulfonamide 9 in the presence of varying 
levels of sulfide acceptor substrate, as described above.   
Sulfide Azide TTN 8a TTN 9 
0.5eq 1 eq 71 110 
1 eq 1 eq 97 100 
2 eq 1 eq 110 93 
3 eq 1 eq 130 85 
4 eq 1 eq 140 80 
 
 
 
Figure S11. TTN values measured for slow addition vs. adding substrates 
simultaneously, using P411BM3-CIS T438S enzyme and the substrates shown in Figure 
S10.  Light gray bar shows TTN for sulfonamide, 9, dark gray shows TTN for the 
sulfimide, 8a.  
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C h a p t e r  4  
ENZYME-CONTROLLED NITROGEN-ATOM TRANSFER ENABLES 
REGIODIVERGENT C–H AMINATION 
 
 
 
 
 
 
 
 
 
This chapter is published as T. K. Hyster, C. C. Farwell, A. R. Buller, J. A. McIntosh, F. H. 
Arnold  “Enzyme-controlled nitrogen-atom transfer enables regiodivergent C–H 
amination.” in Journal of the American Chemical Society. 2014, 136, 15505-15509.  T.K.H 
synthesized all compounds, and performed initial rate experiments.  I conducted enzyme 
characterization, library construction and screening, and crystallographic analysis of an 
engineered enzyme variant. 
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Abstract 
We recently demonstrated that variants of cytochrome P450BM3 (CYP102A1) catalyze the 
insertion of nitrogen species into benzylic C–H bonds to form new C–N bonds. An 
outstanding challenge in the field of C–H amination is catalyst-controlled 
regioselectivity. Here, we report two engineered variants of P450BM3 that provide 
divergent regioselectivity for C–H amination, one favoring amination of benzylic C–H 
bonds while the other favors homo-benzylic C–H bonds. The two variants provide nearly 
identical kinetic isotope effect (KIE) values (2.8-3.0) that suggest C–H abstraction is rate 
limiting. The 2.66-Å crystal structure of the most active enzyme suggests that the 
engineered active site can preorganize the substrate for reactivity. We hypothesize that the 
enzyme controls regioselectivity through localization of a single C–H bond close to the 
iron nitrenoid. 
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Main Text 
The presence of nitrogen atoms in the vast majority of drugs drives the search for 
efficient and selective methods to form new C–N bonds.1 Traditional approaches for 
forming aliphatic C–N bonds utilize the intrinsic nucleophilicity of nitrogen and the 
electrophilicity of a vast array of carbon species to facilitate bond formation.2 Nature 
utilizes a similar reactivity profile, as exemplified by transaminase and amino acid 
dehydrogenase enzymes.3 An alternative means to C–N bond formation reverses the 
traditional reactivity profiles by utilizing an electrophilic nitrogen species.4 This is 
typically achieved via generation of a transition metal-bound nitrenoid intermediate that 
can react with alkenes, nucleophilic heteroatoms, and C–H bonds.5 This approach is 
attractive because new C–N bonds can be accessed directly from unactivated carbon 
atoms.  
With the exception of the unusual cytochrome P450 TxtE-catalyzed nitration of 
tryptophan,6 the machinery to generate and use electrophilic nitrogen species has not 
been found in nature. Cytochrome P450s, however, have evolved to generate and use 
electrophilic oxygen species capable of reacting with alkenes, heteroatoms, and C–H 
bonds.7 This feat is possible because P450s can form a highly reactive iron-oxo 
intermediate known as compound I.8 Inspired by the similarity between compound I and 
the carbenoid and nitrenoid intermediates invoked in transition metal-catalyzed reactions, 
our group recently discovered that P450s could catalyze reactions thought to proceed 
through these intermediates.9,10,11,12 
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C–H amination activity is particularly sensitive to the nature of the residue 
ligating the axial position of the iron-heme prosthetic group, with serine-ligated P411BM3 
variants providing reactivity superior to cysteine-ligated variants in the amination of 
secondary benzylic C–H bonds (Scheme 1).11 We refer to the serine-ligated enzymes as 
P411s, because the diagnostic Soret peak shifts from 450 nm (cysteine-ligated) to 411 nm 
and the enzymes no longer catalyze their native oxygenation reactions. Complementary 
work by Fasan showed that variants of P450BM3 and other hemoproteins bearing different 
axial ligands (cysteine, histidine, or tyrosine) will catalyze this type of transformation, 
although they require more activated tertiary benzylic C–H bonds to >50% yield.13 The 
need for relatively weak C–H bonds (BDE ≤ 85) can be understood, in part, by 
considering the reaction mechanism.14 Iron-catalyzed aminations are understood to 
proceed via a mechanism in some ways reminiscent of P450-catalyzed C–H oxidation, 
where C–H bond cleavage generates a radical species that can rebound to form the new 
C–N bond.15 White found that the C–H cleavage is sensitive to bond strength, where C–H 
bonds with lower bond dissociation energies (BDE) are aminated preferentially to C–H 
bonds with greater BDE.16 Fasan corroborated this result using enzymes, reporting a 
linear relationship between reaction rate and C–H bond strength.13b 
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Scheme 1. Enzyme-catalyzed C–H amination. 
This observation indicates that it could be challenging to aminate strong C–H 
bonds of substrates having alternative, weak C–H bonds. Given that C–H amination is 
kinetically controlled, Du Bois found that substrate geometry can influence selectivity. 
Rather than substrate control, it would be more attractive to have selectivity controlled by 
the catalyst, such that different products could be generated from a single starting 
material, depending on the catalyst. In select examples, Du Bois and Katsuki found that 
modulating the steric properties of the ligand on rhodium and iridium catalysts can shift 
selectivity in favor of stronger, but less hindered, C–H bonds.17 
We hypothesized that enzymes could provide an elegant solution to this 
regioselectivity challenge. Since P450s can be engineered to alter the regioselectivity of 
hydroxylation,18 we imagined that active site engineering could similarly generate 
catalysts with high selectivity for amination (Scheme 1). As a model system, we selected 
2,5-di-n-propyl benzene sulfonyl azide 1 because it contains two potential sites for C–H 
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amination: the benzylic position (α-position) and the homo-benzylic position (β-
position) with disparate C–H bond strengths (85 kcal/mol and 98 kcal/mol).19 
Furthermore, Zhang showed that this substrate could undergo amination of both positions 
under cobalt-porphyrin catalysis, although amination of the α-position was favored.20 
We began by testing variants from our previous reports on C–H amination and 
sulfimidation.11,21 The best variant was P411BM3-CIS-T438S (15 mutations from wild 
type). It gave low activity with sulfonylazide 1 (32 TTN) (Table 1, entry 1), but was 
modestly selective for β-amination (84:16), establishing that a P411-based amination 
biocatalyst is capable of cleaving bonds significantly stronger than previously reported.  
Expanded active sites have been key for superior reactivity in some of our 
previous studies.21,22 Unfortunately, low reactivity and selectivity were observed for 
mutants containing alanine mutations in the active site (Table 1, entries 2-4). We thus 
focused on engineering new variants for amination. We selected five positions in the 
active site, F87, L181, I263, T268, and T438, and screened libraries made by site-
saturation mutagenesis at each position in the P411BM3-CIS-T438S parent. Mutation at 
four of the positions failed to provide more-active variants. The I263 library, however, 
yielded a substantially improved enzyme: variant P411BM3-CIS-T438S-I263F showed an 
11-fold increase in activity and 97:3 selectivity favoring amination at the β-position 
(Table 1, entry 5). Reverting the previously identified activating mutations C400S and 
T268A decreased the desired reactivity, confirming their importance to catalysis (Table 1, 
entries 6-7).11 
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Table 1. Comparison of activities (TTN) and regioselectivities of P411BM3 variants 
for the reaction of azide 1 to sultams 2 and 3. 
 
 
In the course of screening site saturation mutagenesis libraries, F87A was 
identified as a mutation that switched selectivity to favor amination at the α-position, 
albeit with low turnover (Table 1, entry 8). Since F87A is present in many P450BM3 
variants engineered as hydroxylation catalysts, we elected to screen a set of F87A 
variants to determine if this mutation would continue to provide selectivity for the α-
n-Pr
n-Pr
S
O O
NHSn-Pr
O O
Me
β + NH
S
Et
α
O O
Enzyme
25 οC, 12 hr
Entry Catalyst TTN 2:3 
1 P411BM3-CIS-T438S 32 84:16 
2 P411BM3-H2-5-F10 56 53:47 
3 P411BM3-H2-4-D4 19 66:44 
4 P411BM3-H2-A10 31 44:54 
5 P411BM3-CIS-T438S-I263F 361 97:3 
6 P450BM3-CIS-T438S-I263F <1 n.d. 
7 P411BM3-CIS-T438S-I263F-A268T 12 33:64 
8 P411BM3-CIS-T438S-F87A 70 25:75 
9 P411BM3-T268A-F87A 187 30:70 
10 P411BM3-B1-T268A-M263I 35 38:62 
11 P411BM3-Man1-T268A 7 34:66 
12 P411BM3-T268A-F87V 25 99:1 
13 P411BM3-CIS-T438S-I263F-F87A 10 66:34 
1 2 3
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position in those variants and whether the additional mutations could further increase 
activity. In all cases tested, the F87A mutation favored α-amination, albeit with low levels 
of activity (Table 1, entries 9-11). The most active variant is P411BM3-T268A-F87A (3 
mutations from wild type), providing 187 TTNs and modest selectivity (30:70 (2:3)) for 
the α-amination product (Table 1, entry 9). Reverting the F87A mutation to F87V (the 
mutation present in the P411BM3-CIS backbone) switched the selectivity to the to 6-
position, demonstrating the importance of the residue at this position for controlling C–H 
amination regioselectivity (Table 1, entry 12). We were also interested in testing the 
impact of F87A in the presence of the I263F mutation. The double F87A+I263F variant 
continued to be selective for β-amination, but with substantially decreased selectivity and 
activity (Table 1, entry 13). These results support the lynchpin role of the F87 position in 
controlling the regioselectivity of amination.  
Having identified two enzyme variants with divergent regioselectivity, P411BM3-
CIS-T438S-I263F and P411BM3-T268A-F87A, we then explored the ability of these 
enzymes to control regioselectivity and enantioselectivity on different substrates (Table 
2). In addition to providing excellent regioselectivity, P411BM3-CIS-T438S-I263F and 
P411BM3-T268A-F87A furnished sultams 2 and 3 with excellent enantioselectivity 
(99.5:0.5 er in both cases) (Table 2, entries 1 and 2). These enzymes are effective at 
controlling regioselectivity for substrates bearing longer alkyl chains, although with 
diminished activity (Table 2, entry 4). Surprisingly, P411BM3-T268A-F87A affords even 
greater regioselectivity (3:97 (5:6)) for α-amination on these substrates when compared 
to the parent substrate (Table 3, entry 5). Changing the substituent on the aromatic ring 
  
92 
from an alkyl group to an ester did not negatively impact the reaction. The two variants 
continued to strongly favor their respective regioisomers with good yields and 
comparable enantioselectivies (Table 2, entries 5 and 6).  
In order to gain insight into how these enzymes determine regioselectivity, we 
considered the possibility of mechanistic differences between amination at the α-position 
and β-position. To probe this, we measured the kinetic isotope effects with 1 and D14-1. 
When P411BM3-CIS-T438S-I263F was tested, a 1H-KIE value of 2.8 was observed, 
whereas P411BM3-T268A-F87A afforded a 1H-KIE value of 3.0 (Figures S1 and S2). 
These values are consistent with C–H abstraction being rate-determining in the catalytic 
cycle and suggest a similar C–H cleavage mechanism despite the divergent selectivities. 
Since C–H abstraction is kinetically controlled, reactivity depends on the proximity of the 
C–H bond to the metal nitrenoid. In light of the exquisite regio- and enantioselectivities 
provided by the two P411 variants, we hypothesize that the enzyme active sites situate the 
substrate such that a different C–H bond is kinetically accessible in each variant.  
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Table 2. Comparison of activities (TTN), regioselectivities, and enantioselectivities for 
azides 1, 4, and 7 with P411BM3-CIS-T438S-I263F and P411BM3-T268A-F87A 
 
a e.r. = enantiomeric ratio. 
 
n-Pr
n-Pr
S
O O
NHSn-Pr
O O
Me
β + NH
S
Et
α
O O
Enzyme
25 οC, 12 hr
1 2 3
n-Bu
n-Bu
S
O O
NHSn-Bu
O O
Et
β + NH
S
n-Pr
α
O O
Enzyme
25 οC, 12 hr
4 5 6
Variant TTN Selectivity 2:3 e.r.a (2) e.r. (3) 
P411BM3-CIS-T438S-I263F 361 97:3 99.5 : 0.5 
P411BM3-T268A-F87A 187 30:70 99 : 1 
Variant TTN Selectivity 5:6 e.r.a (5) e.r. (6) 
P411BM3-CIS-T438S-I263F 178 90:10 99.5 : 0.5 
P411BM3-T268A-F87A 128 3:97 99.5 : 0.5 
EtO2C
n-Pr
S
O O
NHSn-Bu
O O
Me
β + NH
S
Et
α
O O
Enzyme
25 οC, 12 hr
7 8 9
Variant TTN Selectivity 8:9 e.r.a (8) e.r. (9) 
P411BM3-CIS-T438S-I263F 192 95:5 98.5 : 1.5 
P411BM3-T268A-F87A 130 5:95 99.5 : 0.5 
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To aid in understanding how the active site architecture of these P411 enzymes 
controls regioselectivity, we pursued their structural characterization through X-ray 
crystallography. Although high-quality crystals of P411BM3-T268A-F87A were not 
forthcoming, crystals of P411BM3-CIS-T438S-I263F diffracted to 2.66 Å and molecular 
replacement readily yielded a structure. This new structure represents a substantial 
improvement on the previously reported P411BM3-CIS structure, which was determined at 
3.3 Å-resolution.12a The global features remain identical, but the higher resolution data 
enable more-accurate placement of the side chains lining the active site, the heme vinyl 
and propionate moieties, and the position of the L437 sidechain (Figure S3).12a 
Importantly, the F263 sidechain is resolved and populates a non-favored rotamer 
extending into the active site. Interestingly, the location of the F263 sidechain does not 
substantially change the location of the I-helix (on which F263 resides) by comparison to 
the I263 parent. It does, however, cause repacking of the flanking residues on the F-helix 
(Figure S3). Alignment of the structure of P411BM3-CIS-T438S-I263F with that of wild-
type P450BM3 bound to palmitoic acid shows that I263F occludes binding of the native 
substrate. This is consistent with previous reports that showed that the I263F mutation 
shut down the native hydroxylation activity.23 Docking the sultam product into the active 
site clearly demonstrates that I263F is positioned to pack against the benzene ring of the 
substrate. These complementary van Der Waals interactions could decrease the 
conformational freedom of the nitrenoid intermediate and thereby promote reactivity at 
the higher-energy C–H bond (Figure S5). 
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In summary, we have discovered two P411BM3 variants that offer different and 
complementary regioselectivities for C–H amination. Mutation at the F87 position is 
crucial for controlling selectivity, with F87V favoring the β-amination of 2,5-
disubstituted benzene sulfonyl azides, whereas F87A favors α-amination. Introduction of 
phenylalanine at position I263 provides a 11-fold increase in β-amination activity. Given 
that the C–H cleavage is rate-limiting, regioselectivity is likely kinetically controlled, 
wherein the C–H bond cleaved is the one closest to the iron-nitrenoid, as dictated by the 
enzyme. Crystallographic analysis reveals that the I263F mutation has little effect on the 
secondary and tertiary structure of the protein and primarily decreases the volume of the 
active site.  
While catalyst-controlled divergent regioselectivity remains a challenge for small 
molecule catalysts, enzyme catalysts can be readily engineered by mutagenesis and 
screening for the desired selectivity.  Combined with their ability to take on non-natural 
activities such as direct C–H amination, enzymes represent a versatile platform for 
catalyst development to solve challenging selectivity problems in organic chemistry. 
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1. Materials and Methods 
Small scale reaction conditions were as described in Chapter 2.  Protein expression, 
purification, and molecular cloning protocols were performed as described in 
Chapter 3.   
Reaction screening in 96-well plate format. Site-saturation libraries were generated by 
employing the “22-codon” method.24 E. coli libraries were generated and culture in 200 
µL of LBAMP and stored as glycerol stocks at -80 ºC in 96-well plates. 50 µL of the 
preculture was transferred to a 1200 µL of Hyperbroth using a multichannel pipette. The 
cultures were incubated at 37 ºC, 200 rpm, 80% humidity until the OD600 = 4 (approx. 2.5 
hours). The plates were cooled on ice for 30 minutes before expression was induced (0.5 
mM IPTG, 1 mM Ala final concentration. Expression was conducted at 20 ºC, 180 rpm, 
20 hours. The cells were pelleted (4000 x g, 10 min, 4 ºC) and the 96-well plate was 
transferred to an anaerobic chamber. The pellets were resuspended in 300 µL argon 
sparged reaction buffer (4:1 M9-N/glucose (250 mM)). GOX solution (10x, 40 µL/well) 
was added to each well followed by azide 1 (100 mM, 10 µL/well). The plate was sealed 
with aluminum sealing tape, removed from the anaerobic chamber, and shaken at 40 rpm. 
After 12 hours, the seal was removed and 500 µL of acetonitrile and 10 µL of standard 
(10 mM) were added to each well. The plate was vortexed and centrifuged (4000g, 30 
minutes) and 500 µL aliquots were transferred to a shallow-well plate for analysis by 
HPLC. 
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TABLE S1: Mutations (relative to wild-type P450BM3) in enzymes used in this study. 
 
Enzyme Mutations relative to wild-type P450BM3 
P450BM3 None 
P411BM3-T268A C400S-T268A 
P450BM3-CIS V78A, F87V, P142S, T175I, A184V, 
S226R, H236Q, E252G, T268A, A290V, 
L353V, I366V, E442K 
P411BM3-CIS P450BM3-CIS C400S 
P411BM3-H2-5-F10 P411BM3-CIS L75A, I263A, L437A 
P411BM3-H2-4-D4 P411BM3-CIS M177A, L181A, L437A 
P411BM3-H2-A10 P411BM3-CIS L75A, L181A 
P411BM3-CIS-T438S P411BM3-CIS T438S 
P411BM3-CIS-T438S-I263F P411BM3-CIS T438S, I263F 
P411BM3-CIS-T438S-I263F-A268T P411BM3-CIS T438S, I263F, A268T 
P450BM3-CIS-T438S-I263F P450BM3-CIS T438S, I263F 
P411BM3-MAN1-T268A V78A, F81L, A82T, F87A, P142S, T175I, 
A184V, F205C, S226R, H236Q, E252G, 
R255S, A290V, L353V, C400S  
P411BM3-MAN1-T268A-M263I V78L, F87A, P142S, T175I, A184T, 
F205C, S226R, H236Q, E252G, R255S, 
A290V, G315S, A330V, L353V, T268A, 
C400S 
P411BM3-T268A-F87A C400S-T268A-F87A 
P411BM3-T268A-F87V C400S-T268A-F87V 
P411BM3-CIS-T438S-I263F-F87A P411BM3-CIS T438S, I263F 
 
2. Determination of reaction rates 
Determination of initial rates. All initial rate experiments were set up in an anaerobic 
chamber. Four 2-ml vials were charged with a stir bar, GOX 10x (40 µL), glucose (250 
mM, 40 µL), NADPH (20 mM, 40 µL), and KPi (pH = 8.0, 0.1 M, 260 µL). The vials 
were sealed with a silicon crimp cap and removed from the anaerobic chamber. The 
reactions were placed on a stir plate and charged with azide 1 or azide 1’ (100 mM, 10 
µL). The reactions were quenched at 2-3 minute intervals over 8-12 minutes by 
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decapping and adding acetone (500 µL) and internal standard (1,3,5-
trimethoxybenzene 10 mM, 10 µL) . After 5 minutes of stirring, the reaction mixtures 
were transferred to 1.8 mL tubes, which were vortexed and centrifuged (14,000 x g, 10 
min). The supernatant was transferred to a vial for analysis by HPLC. Kinetic isotope 
effects for P411BM3-CIS-T438S-I263F and P411BM3-T268A-F87A are plotted in Figures 
S2 and S3. 
Figure S1. Initial Rate Plots of Azide 1 (blue diamonds) and Azide 1’ (red squares) with 
P411BM3-CIS-T438S-I263F. Each point is an average of 3 runs.  
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Figure S2. Initial Rate Plots of Azide 1 (blue diamonds) and Azide 1’ (red squares) 
with P411BM3-T268A-F87A. Each point is an average of 3 runs.  
 
 
 
 
3. Crystal structure of P411BM3-CIS-T438S-I263F 
Crystallization, data collection, and structure determination. The heme domain of 
P411BM3-CIS-T438S-I263F was purified, flash frozen in liquid N2, and stored at -80 °C 
until crystallization. Sitting drop vapor diffusion experiments were performed by 
generating a 1:1 mixture of protein stock (12 mg/mL in 0.1 M KPi, pH = 8.0) and well 
solution in a 96-well sitting-drop plate with a final drop volume of 0.4 µL and a reservoir 
volume of 400 µL. Crystals grew over 5-10 days in 0.1 M Tris/HCl (pH = 7.0), 2.0 M 
ammonium sulfate, 0.2 M lithium sulfate. Crystals were cryoprotected by immersion into 
well solution with 20% glycerol before being flash-frozen in liquid N2. Diffraction data 
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were collected on the Stanford Synchrotron Radiation Laboratory Beamline 12-2. Data 
were processed using XDS in the spacegroup P42212 to 2.66 Å resolution.25 
The structure of P411BM3-CIS-T438S-I263F was solved by molecular replacement 
using the Phaser program,26 as implemented in CCP4,27 using the P411BM3-CIS structure 
[PDB ID: 4H23] as the search model. Model building was performed in Coot and 
restrained refinement in Refmac5.28 Model quality was assessed with the MolProbity 
online server.29 TLS operators were included in the last round of refinement.30 
Crystallographic and model statistics are described in Table S1. 
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Table S2. Data processing and refinement statistics 
 
 
Data processing P411BM3-CIS-T438S-I263F 
Wavelength  
Spacegroup P42212 
Unit cell dimensions  = 90° 
    a = b , c             206.9 , 119.39 
    α = β = γ 90 
Beamline SSRL 12-2 
Wavelength 0.9795 Å 
Resolution (Å) 39.1 – 2.66 
Last bin (Å) 2.8 – 2.66 
Number of Observations 1,031,477 
Completeness (%) 100 (100) 
Rmeas (%) 0.25 (2.1) 
Rpim (%) 0.067 (0.550) 
I/σI 11.0 (1.44) 
CC1/2 0.996 (0.534) 
Redundancy 13.8 (14.5) 
  
Refinement   
Number of reflections 70732 
Number of atoms 10947 
Last bin (Å) 2.73 – 2.66 
Rwork 19.7 (34.7) 
Rfree 23.5 (37.5) 
Average B factor (Å2) 36.2 
Ramachandran Plot  
     Most favored (%) 96.4 
     Allowed (%) 99.9 
     Outliers (%) 0.1 
Values in parenthesis are for the highest resolution shell; 
Rmerge is Σ|Io – I| / ΣIo , where Io is the intensity of an individual reflection, and I is the mean intensity for 
multiply recorded reflections; 
Rpim is 1/(N-1) Σ|Io – I| / ΣIo, where N is the number of observations for a given reflection; 
Rwork is ||Fo – Fc|| / Fo, where Fo is an observed amplitude and Fc a calculated amplitude; 
Rfree is the same statistic calculated over a 5.1% subset of the data that has not been included during 
refinement. 
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Figure S3. P411BM3-CIS-T438S-I263F (blue) and P411BM3-CIS-T438S (green) overlaid 
with key residues displayed and labeled. 
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Figure S4. (Left) P411BM3-CIS-T438S-I263F (blue) occluding C16-C18 of PAM. 
(Right) and P450BM3 (green) containing PAM.  
 
 
 
 
 
 
 
 
 
 
  
  
105 
Figure S5. Docking Model of Sultam 3 covalently bound to heme with P411BM3-CIS-
T438S-I263F. Docking done using Autodock Vina.31 
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4. Synthetic Procedures 
 
Sultams 2 and 3 were previously reported by Katsuki.32 
 
 
 
 
 
ethyl 3-methyl-3,4-dihydro-2H-benzo[e][1,2]thiazine-7-carboxylate 1,1-dioxide (9) 
 
1H 500 MHz (DMSO d6): 8.17 (d, 1H, J = 1.8 Hz), 8.06 (d, 1H, J = 1.8, 8.2 Hz), 7.53 (m, 
2H), 4.34 (q, 2H, J = 7.25 Hz), 3.83 (m, 1H), 3.06 (dd, 1H, J = 17.6, 3.7 Hz), 2.79 (dd, 1H, 
J = 17.6, 11.4 Hz), 1.34 (3H, t, J = 7.1 Hz), 1.28 (3H, d, J = 6.6 Hz).  
 
13C 125 MHz (DMSO d6): 164.4, 141.4, 137.9, 131.8, 130.7, 128.9, 123.7, 61.3, 48.6, 
34.9, 21.0, 14.1.  
 
 
 
 
ethyl 3-ethyl-2,3-dihydrobenzo[d]isothiazole-6-carboxylate 1,1-dioxide (10) 
 
1H 500 MHz (DMSO d6): 8.23 (dd, 1H, J = 8.1, 1.5 Hz), 8.20 (d, 1H, J = 1.5 Hz), 8.16 (d, 
1H, J = 4.2 Hz), 7.77 (d, 1H, J = 8.1 Hz), 4.72 (ap p, 1H, J = 4.0 Hz), 4.37 (q, 2H, J = 7.1 
Hz), 1.97 (m, 1H), 1.68 (m, 1H), 1.35 (t, 3H, J = 7.1 Hz), 0.90 (t, 3H, J = 7.3 Hz). 
 
13C 125 MHz (DMSO d6): 164.3, 145.3, 136.9, 133.3, 131.1, 125.7, 121.1, 61.5, 58.2, 
27.9, 14.1, 9.8.  
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C h a p t e r  5  
ENANTIOSELECTIVE ENZYME-CATALYZED AZIRIDINATION ENABLED BY 
ACTIVE-SITE ENGINEERING OF A CYTOCHROME P450 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is prepared for submission to ACS Central Science as C. C. Farwell, R. K. 
Zhang, J. A. McIntosh, T. K. Hyster, F. H. Arnold  “Enantioselective enzyme-catalyzed 
aziridination enabled by active-site engineering of a cytochrome P450.” I performed all 
initial characterization of the enzymatic aziridination reaction, including discovery of the 
beneficial effects of I263F in this reaction. R.K.Z. synthesized product standards, 
quantified reaction products, and performed enzyme mutagenesis and screening for 
aziridination.  J.A.M and T.K.H. performed analytical experiments to characterize the 
initial reaction.  Myself and F.H.A. wrote the paper.   
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Abstract 
One of the greatest challenges in protein design is creating new enzymes, something 
evolution does all the time.  Using some of nature’s evolutionary tricks, we have 
engineered a bacterial cytochrome P450 to catalyze highly enantioselective intermolecular 
aziridination, a synthetically useful reaction that has no natural biological counterpart. The 
new enzyme is fully genetically encoded and can be optimized rapidly by protein 
engineering to exhibit very high enantioselectivity (up to 99% ee) and high activity (>1,000 
catalytic turnovers) for intermolecular aziridination, demonstrated here with tosyl azide and 
substituted styrenes. Together with carbene (olefin cyclopropanation and N-H insertion) 
and nitrene transfer (C–H amination and sulfimidation) activities reported previously, this 
new aziridination activity highlights the remarkable ability of a natural enzyme to adapt to 
non-natural substrates and take on new functions. Once discovered in an evolvable enzyme 
such as the P450, non-natural reactivity can be improved and selectivity tuned by protein 
engineering to create a new catalyst family.    
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Introduction 
The impressive catalytic diversity of enzymes illustrates the breadth of reaction 
space explored throughout biological evolution. Chemists are taking advantage of this vast 
repository of biocatalysts for chemical synthesis; they are also mimicking nature’s 
engineering strategy of mutation and selection to optimize enzyme function for a myriad of 
applications.1 A remaining challenge is to create new enzymes for the many useful 
reactions that are not known in the biological world.  We and others have argued that 
learning from nature’s mechanisms for catalytic innovation—exploiting enzyme catalytic 
promiscuity and retaining key elements of structure and mechanism while exploring new 
functions—can help us discover new biocatalysts starting from nature’s vast repertoire.2 
The discovery and optimization of enzyme catalysts for non-natural reactions has provided 
alternative routes to important molecules that would otherwise be unattainable through 
biocatalysis.3  
Our group4 and that of Rudi Fasan5 recently reported that heme proteins can 
catalyze intramolecular direct C–H amination via formation of reactive metallonitrenoid 
species and nitrene transfer.  We extended this novel biocatalytic activation mode to 
intermolecular sulfimidation and showed that the enzyme, derived from a cytochrome 
P450, could be tuned by mutation to catalyze the reaction with good activity and moderate 
enantioselectivity (Scheme 1A).6 Carrying out non-natural reactions with an enzyme 
provides the opportunity for unprecedented control over selectivity: we recently showed, 
for example, that engineering the active site could even override the preference for sites 
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with lower bond dissociation energies that governs regioselectivity of small-molecule 
C-H amination catalysts.7   
Among the various nitrene transfer reactions used in synthetic chemistry, 
aziridination with azide nitrene sources is a compelling transformation (Scheme 1B), given 
its high atom-economy and the utility of the aziridine functional group in chemical 
synthesis.8 The oxygen equivalent to aziridines, epoxides, are prevalent in natural products, 
and their biosynthesis involves oxygenation via enzyme-activated electrophilic oxygen 
species.9 However, aside from the TxtE-catalyzed nitration of tryptophan,10 no natural 
enzyme is known to use electrophilic nitrogen species for the direct transfer of nitrogen 
atoms to olefins or C-H bonds. Aziridine rings are much less common in natural products 
than epoxides, and aziridine biosynthesis is believed to involve intramolecular nucleophilic 
displacement (e.g., activation by vicinal alcohols, as depicted in Figure 1).11 This step is 
thought to occur late in biosynthesis and can involve anchoring of the substrate to peptidyl 
carrier proteins (Figure 1).  The dearth of knowledge about the enzymes responsible for this 
transformation, along with the extremely limited set of substrates investigated so far, makes 
applying natural aziridination pathways for chemical synthesis infeasible.  An enzymatic 
reaction analogous to epoxidation would be highly attractive given the utility of 
enantioselective convergent synthesis with electrophilic metal-nitrogen species.12    
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Scheme 1. Enzyme-catalyzed intermolecular nitrogen-atom transfer 
 
 
In our previous work on the intermolecular imidation of sulfides catalyzed by 
variants of cytochrome P450BM3, two factors appeared to limit reactivity. First, the reaction 
was promoted by electron-rich sulfides, and second, enzyme-catalyzed azide reduction 
represented a significant side reaction, particularly with less reactive, electron-deficient 
sulfides.6  Increasing the sulfide substrate loading improved the sulfimide product to side 
product ratio, which suggested that increasing the effective concentration of sulfide ‘nitrene 
acceptor’ in the enzyme active site might improve sulfimidation productivity. Given the 
less reactive nature of olefins relative to sulfides along with operational limitations to 
increasing olefin effective concentration (i.e., their limited solubility in aqueous media), we 
surmised that intermolecular aziridination would be a challenging activation mode for the 
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enzyme.  However, we hypothesized that protein engineering would allow us to 
circumvent these limitations if the enzyme could more effectively bind and orient the 
substrates in the enzyme active site for productive nitrene transfer. Here we demonstrate 
that active-site engineering can indeed enable intermolecular enzyme-catalyzed nitrene 
transfer to olefins.  
 
Results and Discussion 
We started this investigation of enzyme-catalyzed aziridination with an engineered 
variant of cytochrome P450BM3, P411BM3-CIS-T438S, found previously to be effective for 
intramolecular C–H amination and sulfide imidation (see table S1 for mutations from wild-
type P450BM3).4b,6 We call this enzyme a “P411” due to mutation of the cysteine residue 
that coordinates the heme iron to serine (C400S), which changes the characteristic CO-
bound Soret peak from 450 to 411 nm.4b,7,14 This axial cysteine is completely conserved 
among the cytochrome P450s and is required for the native monooxygenation activity. 
Thus the P411 enzyme is no longer a ‘cytochrome P450’, nor does it exhibit its native 
monooxygenation activity.14-15  However, the C400S mutation increases the non-natural 
carbene and nitrene transfer activities of P450BM3.4b,6-7,14  Two crystal structures of P411 
variants of P450BM3 show that the serine coordinates the iron and causes no significant 
structural perturbation in the substrate binding pocket.7,14   
Mechanistic analysis of sulfide imidation suggested that electron-rich sulfides 
promote nitrene transfer.6  Reasoning that aziridination could also be influenced by the 
electronic properties of the olefin substrate, we tested reactivity towards 4-methoxystyrene, 
bearing the strong electron-inducing p-OMe substituent, and tosyl azide (TsN3) as the 
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nitrene precursor (Figure 2). The major product of the reaction was tosyl sulfonamide 3, 
as also observed with intermolecular imidation of sulfides.6 The minor product was not the 
aziridine, however, but amido-alcohol 2.  Control experiments showed that a synthetic 
aziridine standard (S1) rapidly decomposes under aqueous reaction conditions to the 
corresponding amido-alcohol 2 (Figure S1). Degradation of this aziridine product has also 
been observed in studies with small-molecule catalysts.16 We therefore inferred that 
production of 2 is directly related to the nitrene transfer activity of the enzyme towards this 
olefin substrate.  
Table 1. Total turnovers (TTN) to product and enantioselectivities for aziridination 
catalyzed by P411BM3-CIS-T438S (P) and P411BM3-CIS-T438S-I263F (P-I263F) with 
selected styrenyl olefins 1, 3, and 5 and tosyl azide using purified holoenzymes.  
Reactions were done in 0.1 M KPi buffer pH = 8.0 using NADPH as reductant, using 0.2 
mol% enzyme, with 2.5 mM TsN3 and 7.5 mM styrene.  Detailed reaction conditions can 
be found in the supporting information.    
 
 
a  TTN = Total turnover number. b % ee determined as ((S – R)/ (S + R)) for S-selective reactions, and ((R – 
S)/(R + S)) for the R-selective reaction, nd = not determined,  rac = racemic. 
 
MeO
NHTs
OH
or
NTs
R R
R = Me, 4
R = H, 62
Enzyme
TsN3
R = -OMe, 1
R = -Me, 3
R = -H, 5
anaerobic
4h, RT
!
!
Product!
P411BM3-CIS-T438S (P)! P-I263F!
TTN! % ee! TTN! % ee!
2! 15! rac! 150! rac!
4! 8! nd! 160! 70 (S)!
6! 5! nd! 190! 74 (S)!
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The low level of nitrene transfer activity to 4-methoxystyrene with P411BM3-
CIS-T438S prompted us to investigate other enzyme variants.  We chose a small set of 
cytochrome P450BM3 variants and heme proteins prepared for other studies in order to 
assess how changes in the protein sequence affect nitrene transfer to olefin substrates 
(Tables S1 and S2). P450BM3 sequences lacking the C400S and/or T268A mutations6-7 were 
not productive in the aziridination reaction. Nor did the Fe(II)-protoporphyrin IX (PPIX) 
cofactor catalyze aziridination under these conditions. (In previous work we found that 
Fe(II)-PPIX was active for intramolecular C–H bond amination, depending on the C-H 
bond strength,4 but did not catalyze intermolecular nitrene transfer to sulfides.6) Mutants 
differing from P411BM3-CIS-T438S by 2-5 alanine mutations in the active site17 showed 
some aziridination activity (4-8 TTN), but none was more productive than P411BM3-CIS-
T438S. We also tested a set of enzymes containing different axial mutations, including the 
S400H, S400D, and S400M mutants of P411BM3-CIS-T438S.  These enzymes were also 
only weakly active, giving 2 at levels similar to P411BM3-CIS-T438S (3-4 TTN). 
Myoglobin (horse heart), cytochrome c (bovine heart), and cytochrome P450Rhf (from 
Rhodococcus sp. NCIMB 9784) were all inactive for this intermolecular aziridination 
(Table S2).  The thermostable cytochrome P450 CYP119 from Sulfolobus sulfataricus with 
the axial C317S mutation18 did catalyze aziridination (~ 7 TTN), demonstrating that axial 
mutants of other cytochrome P450s may be active and suitable starting points for further 
engineering.  
Of all the enzymes tested, a variant of P411BM3-CIS-T438S having a single active-
site substitution, I263F, was the most reactive toward 4-methoxystyrene by a wide margin 
(150 TTN, Table 1).  This variant, which promoted regioselective intramolecular C–H 
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amination in a previous study,7 supported aziridination at 10-fold increased total 
turnover compared to the P411BM3-CIS-T438S parent enzyme. Comparison of these two 
enzymes’ activities with a set of styrenyl olefins showed that the I263F variant was also 
more productive with the comparatively electron-deficient 4-methylstyrene (4) and styrene 
(6) substrates.  Furthermore, P411BM3-CIS-T438S-I263F (henceforth referred to as P-
I263F) is more active with styrenes 4 and 6 than with 4-methoxystyrene 1. This trend in 
substrate specificity is inverted compared to the parent enzyme (Table 1) and the 
previously observed trend for intermolecular imidation of sulfides.6 Unlike the aziridine 
product that leads to 2, aziridine products 4 and 6 were stable in the reaction conditions. 
The P411BM3-CIS-T438S-I263F variant displayed moderate S enantioselectivity with 4-
methylstyrene and styrene (70 and 74% ee (S), respectively). Racemic product was 
observed for both enzymes with 4-methoxystyrene 1, consistent with non-enzymatic 
degradation of the aziridine to amido-alcohol 2.  
The P-I263F enzyme was even more productive when the reactions were carried 
out using whole E. coli cells expressing this enzyme (Figure S2).  These observations are 
consistent with previous studies demonstrating improved enzyme-catalyzed metal nitrenoid 
and carbenoid transfer in whole-cell reactions.4, 14 No aziridine product was observed when 
cells without enzyme were used, although tosyl azide was converted to tosyl sulfonamide 
over the course of the reaction, consistent with previous observations  (7, Table 2).4  
Indeed, the P-I263F enzyme gave enough product in whole-cell reactions to allow for 
screening in 96-well plate format (see supporting material for library construction and 
screening procedures). Having observed a large increase in aziridination activity upon a 
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single active site mutation, we attempted to improve the activity further by performing 
saturation mutagenesis at selected active site residues and screening for product formation 
by HPLC. Site-saturation mutagenesis (SSM) libraries were created in P-I263F at several 
active-site positions that were previously shown to influence productivity and 
enantioselectivity in non-natural reactions (A78, L181, T268, A328).3a,7 Screening of these 
single SSM libraries on 4-methylstyrene for aziridination productivity revealed one hit, P-
I263F-A328V, with slightly improved TTN values but substantially improved  % ee (96% 
ee, Table 2).  Another round of SSM was performed on this variant at additional active site 
positions (A82, F87, L437, T438).  A second hit was isolated, P-I263F-A328V-L437V, 
with further improved aziridination productivity.  Although yield improvements were 
modest (40% 5 with P-I263F to 43% with P-I263F-A328V and 58% with P-I263F-A328V-
L437V, Table 2), a very significant increase in enantioselectivity, up to > 99% ee (S), was 
observed with the A328V-L437V double mutant.  The P-I263F-L437V and P-I263F-
A328V single mutants were both less productive and less selective than the P-I263F-
A328V-L437V double mutant, demonstrating that the two mutations both contribute to 
achieving this very high enantioselectivity.   
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Table 2. Improvement in yield and % ee for aziridine product 4 with active-site 
engineering starting with P411BM3CIS-T438S (P). Reactions were carried out using whole 
E. coli cells resuspended in M9-N reaction buffer under anaerobic conditions. Yield is 
based on TsN3.  See SI methods for detailed reaction set up and quantification procedures. 
 
  
We hypothesized that the improved aziridine yield observed with P-I263F-A328V-
L437V might stem from a decrease in the rate of azide reduction catalyzed by the evolved 
enzyme. Initial rate measurements performed using purified enzymes are consistent with 
this view, showing decreased rates of azide reduction in P-I263F-A328V (27 min-1) and P-
I263F-A328V-L437V (14 min-1) compared to P-I263F (33 min-1) (Table S4).  Somewhat 
unexpectedly, P-I263F-A328V-L437V also gives a slower rater of aziridination compared 
to P-I263F and P-I263F-A328V (6.0 min-1, 9.7 min-1, and 9.6 min-1, respectively), although 
the relative rate of aziridination to azide reduction was the highest for this enzyme (Table 
S4). Indeed, the productivities of purified enzymes reflect the relative rates of aziridine 
formation to azide reduction, where P-I263F-A328V-L437V shows improved azide 
utilization over the course of the reaction than P-I263F.  
Me
Enzyme
TsN3
Me
NTs
Me
SO2NH2
+
3 4 7
Whole cells
Entry! Enzyme! % yield 4! % yield 7! % ee 4!
1! pET22b-empty! 0! 96! nd!
2! P411BM3-CIS T438S! 1.1! 95! 25!
3! P-I263F! 40! 54! 55!
4! P-I263F-A328V! 43! 50! 96!
5! P-I263F-L437V! 37! 52! 95!
6! P-I263F-A328V-L437V! 58! 40! > 99!
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Having obtained a variant with high enantioselectivity for aziridination of 3, we 
next investigated reactions with different substituted styrene substrates in whole-cell 
reactions (Table 3). As observed with P-I263F, we saw no correlation between the 
electronic inductivity of the aryl substituent and productivity. In general, the evolved 
enzyme was more productive with styrenes substituted at the 4-position, though the highest 
productivity was observed with styrene itself (1020 TTN, entry 2). Both 3-methylstyrene 
and 3-chlorostyrene were significantly less reactive than their 4-substituted counterparts, 
giving 120 and 17 TTN, respectively.  In contrast, 2,4-dimethyl styrene gave 200 TTN, 
suggesting that 2-substitution is less detrimental to reactivity.  The evolved enzyme is 
exceptionally selective with styrene and all 4-substituted styrenes tested, with the exception 
of 4-methoxystyrene, while alternative substitution results in decreased enantioselectivity 
(95% ee and 81% ee for entries 6 and 7, respectively).  Taken together, these results 
suggest that the P-I263F-A328V-L437V enzyme active site is preferentially configured for 
non-substituted and 4-substituted styrene aziridination. Both 4-methoxystyrene and α-
methylstyrene (entries 4 and 9, respectively) gave exclusively racemic amido-alcohol 
product. Formation of the amido-alcohol may result from carbocation stabilization at the 
benzylic position, resulting in decomposition of the aziridine product and subsequent 
carbocation quenching with water.  For these substrates, the resonance and 
hyperconjugative stabilization provided by the p-OMe and α-Me groups is likely 
responsible for this effect. The fact that 4-methoxystyrene and a-methylstyrene both yield a 
racemic mixture of their respective amido-alcohols suggests that the carbocation is 
quenched by water in a step-wise, rather than concerted, process.  
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Table 3. Substrate scope of P-I263F-A328V-L437V enzyme, showing productivity in 
terms of TTN and selectivity in % ee for each product.   
 
a Reaction productivity and enantioselectivity determined as described in SI methods. b % 
ee determined as (S – R)/(S + R). rac = racemic. 
 
The highly enantioselective P-I263F-A328V-L437V variant has three mutations in 
its active site compared to the enzyme used in initial reaction characterization, P411BM3-
Olefin ProductEntry
Cl
NTs
Cl
320
NTs
1020
Me
NTs
Me
500
MeO MeO
OH
NHTs 550
NTs
17Cl Cl
NTsMe Me
120
Me
NTs
Me
200
Me Me
NTs
61
OH
NHTs 51
1
2
3
4
5
6
7
8
9
TTN a % ee b
99
99
95
99
rac
95
81
88
rac
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CIS-T438S. The crystal structure of the heme domain of P-I263F was recently solved 
and shows how the F263 side chain is oriented within the active site, directly above the 
heme cofactor (PDB ID: 4WG2, Figure S2).  Considering I263F in the context of two other 
mutations in P411BM3-CIS-T438S that promote nitrene transfer activity, F87V and T268A, 
provides insight into the effect of active site structure on reaction productivity. Mutation of 
F87 to either V or A can be activating in various P450BM3-catalyzed nitrene transfer 
reactions described so far.2b,4a,6-7   The F87G mutation has been shown to negatively impact 
native fatty acid hydroxylation by P450BM3,19 whereas F87V promotes hydroxylation of 
naphthalene and indole substrates.20 These results suggest steric hindrance at F87 that is 
relieved upon substitution with smaller residues and enhances reactivity with bulkier 
substrates.  Reversion of either T268A or F87V to the wild-type residue in P-I263F reduces 
aziridination productivity (Table S1).  The combined effects of the I263F, F87V, T268A, 
and other active site residues suggest that active site ‘reshaping’ promotes olefin 
aziridination.  The data in Tables 1 and 3 suggest that active site structure can override the 
influence of substrate electronic properties by more effectively orienting substrates in a 
favorable configuration for nitrene transfer to occur.  
The difference between the active sites of P411BM3-CIS-T438S (P) and P-I263F is 
dramatic: the F263 side chain fills space above the heme cofactor whereas the I263 side 
chain is pointed up and away from the heme (Figure S6A and S6B). Given their more 
conservative nature relative to the I263F mutation, the A328V and L437V substitutions 
likely exert only subtle influences on active site structure yet give a significant boost to 
aziridination enantioselectivity (68% ee vs. 99% ee with styrene).  The fact that the 
improved selectivity provided by A328V and L437V comes at the expense of aziridination 
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rates in vitro could suggest that these mutations may block alternative approaches of the 
aziridine, thus leading to decreased rates, but higher selectivities.  The improved overall 
yield in whole cell conditions with P-I263F-A328V-L437V also suggests a role for these 
mutations in a more favorable partition between azide reduction and aziridine formation.  
The rate of nitrene transfer in P411-catalyzed intermolecular sulfimidation 
depended on the electronic properties of the substrates, where more electron-rich sulfides 
gave higher rates of sulfide imidation.6 The productivities of the evolved intermolecular 
aziridination catalysts do not follow this trend: for example, styrene is substantially more 
reactive than the more electron-rich 4-methoxystyrene (Tables 1 and 3). Our results for 
intermolecular aziridination thus suggest that nitrene transfer is driven more by favorable 
substrate binding for aziridination than substrate electronic properties. Analysis of 
regioselective intramolecular C–H amination suggests a similar role for substrate 
positioning by the enzyme in governing the position of C–H amination.7 These 
observations reinforce the strong influence of active site structure in promoting enzyme-
catalyzed intermolecular nitrene transfer. It is possible that further engineering could enable 
the enzyme to catalyze even more challenging reactions such as intermolecular C–H 
amination.   
Conclusions 
 In this first example of enzyme-catalyzed aziridination, we report intermolecular 
aziridination of styrenyl olefins using tosyl azide catalyzed by a serine-ligated “P411” 
variant of cytochrome P450BM3. The specific active site sequence is critical to achieving 
high productivity. Reaction enantioselectivity and productivity could be tuned through 
active-site mutations, such that variant P-I263F-A328V-L437V exhibited very high 
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enantioselectivity (99% ee) and significantly improved azide utilization compared to 
the parental enzyme, P411BM3-CIS-T438S.  Indeed, the results of active site engineering 
for aziridination productivity are consistent with the hypothesis that improving nitrogen-
atom ‘acceptor’ (olefin) binding is a viable route to improving reactivity in 
intermolecular nitrene transfer. These results demonstrate the critical role for protein 
engineering in optimizing non-natural reactivity, and suggest that the well-known 
plasticity of the P450 active site can be leveraged to target challenging chemical 
transformations.  Taking advantage of the catalytic promiscuity of natural enzymes and 
protein engineering will enable us to further expand the reaction space of genetically 
encoded biocatalysts.   
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1.  Materials and Methods 
 
General procedures, protein expression, and protein purification performed as 
described in Chapter 3.   
 
Chromatography. Analytical high-performance liquid chromatography (HPLC) was 
carried out using an Agilent 1200 series, and a Kromasil 100 C18 column (4.6 x 50 mm, 5 
µm). Semi-preparative HPLC was performed using an Agilent XDB-C18 (9.4 x 250 mm, 5 
µm). Analytical chiral HPLC was conducted using a supercritical fluid chromatography 
(SFC) system with isopropanol and liquid CO2 as the mobile phase. Chiral OB-H and AS-
H columns were used to separate aziridine and amido-alcohol enantiomers (4.6 x 150 mm, 
5 µM). Olefins were all commercially available; amido-alcohol and aziridine standards 
were prepared as reported (see Synthetic Procedures).  
 
Typical procedure for small-scale aziridination bioconversions under anaerobic 
conditions using whole cells and purified enzymes. E. coli BL21(DE3) cells containing 
P450 or P411 enzymes were expressed and resuspended to an OD600 = 30 in M9-N), and 
then degassed by sparging with argon in a sealed 6 mL crimp vial for at least 10 minutes. 
To 2 mL crimp vials were added glucose (250 mM in M9-N, 40 µL) and the oxygen 
quenching mixture (14,000 U/ml catalase and 1,000 U/ml glucose oxidase, 20 µL).  The 
headspace of the sealed 2 mL reaction vial was made anaerobic by flushing argon over the 
solution. Resuspended cells (320 µL), followed by olefin substrate (10 µL, 300 mM in 
DMSO) and then tosyl azide (10 µL, 100 mM in DMSO), were added to a 2 mL reaction 
vial via syringe under a continuous flow of argon. Final concentrations of reagents were 
typically: 2.5 mM tosyl azide, 7.5 mM olefin, 25 mM glucose. Sealed reaction vials were 
wrapped in parafilm and shaken (40 rpm) at room temperature for 4 hours.   
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For purified enzyme reactions, a buffer solution composed of 5 mM NADPH 
and 25 mM glucose in 0.1 M KPi pH = 8.0 was prepared and sparged for 20 minutes with 
argon.  Reaction vials were charged with 5 or 7.5 µM enzyme and oxygen quenching 
mixture (as above) and headspaces flushed with argon for 10 minutes.  Degassed buffer 
solution was then added to the vials, followed by olefin substrate and tosyl azide to final 
concentrations of 7.5 mM and 2.5 mM, respectively.  For reactions with myoglobin, 
cytochrome C, CYP119, and P450Rhf, 5 mM sodium dithionite was used as reductant. 
Reactions were quenched by adding acetonitrile (460 µL). The mixture was then 
transferred to a microcentrifuge tube and centrifuged at 14,000 rpm for 5 minutes. The 
solution (540 µL) was transferred to an HPLC vial, charged with internal standard (60 µL, 
10 mM 1,3,5-trichlorobenzene in acetonitrile), and analyzed by HPLC for yield. 
For chiral HPLC reactions were performed on a 2 mL scale with the same 
concentration of reagents using a similar procedure. Chiral HPLC reactions were quenched 
with 2 mL acetonitrile, extracted with ethyl acetate, dried and resuspended in acetone (200 
µL), and purified by C18 semi-preparative HPLC. The purified material was dried, 
resuspended in acetonitrile, and injected onto the chiral HPLC system for analysis. 
 
Reaction screening in 96-well plate format.  
 
Site-saturation libraries were generated by employing the “22-codon” method.21 E. coli 
libraries were generated and cultured in 300 µL of LB with 100 µg/ml ampicillin and stored 
as glycerol stocks at -80 °C in 96-well plates. 50 µL of the pre-culture was transferred to a 
1000 µL of Hyperbroth using a multichannel pipette. The cultures were incubated at 37 °C, 
220 rpm, 80% humidity for 3 hours. The plates were cooled on ice for 15 minutes before 
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expression was induced (0.5 mM IPTG, 1mM 5-aminolevulinic acid final 
concentration). Expression was conducted at 20 °C, 120 rpm, 20 h. The cells were pelleted 
(3000 x g, 5 min) and re-suspended in 40 µL/well oxygen quenching solution. The 96-well 
plate was transferred to an anaerobic chamber. 300 µL per well argon sparged reaction 
buffer (4:1 M9-N : 250mM glucose in M9-N) was added followed by 4-methylstyrene (300 
mM, 10 µL/well) and tosyl azide (100 mM, 10 µL/well). The plate was sealed with 
aluminum sealing tape, removed from the anaerobic chamber, and shaken at 40 rpm. After 
16 hours, the seal was removed and 400 µL of acetonitrile was added to each well. The 
contents of each well were mixed by pipetting up and down using a multichannel pipette. 
Then the plate was centrifuged (4000 x g, 5 minutes) and 500 µL of the supernatant was 
transferred to a shallow-well plate for analysis by HPLC. 
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Table S1.  Panel of P450BM3 enzymes tested for aziridination reactivity with                                
4-methoxystyrene 1.  
 
 
Entry Enzyme  TTN 2  
1 P411BM3-CIS T438S 15 
2 P450BM3-CIS T438S < 1 
3 P450BM3-CIS T438S C400H 3 
4 P450BM3-CIS T438S C400D 4 
5 P450BM3-CIS T438S C400M 4 
6 P411BM3-CIS A268T T438S < 1 
7 P411BM3-H2-5-F10 8 
8 P411BM3-H2-A-10 4 
9 P411BM3-H2-4-D4 5 
10 P450BM3 < 1 
11 P411BM3 3 
12 P450BM3-T268A 2 
13 P411BM3-T268A 4 
14 P411BM3-CIS T438S I263F 150 
14 P411BM3-CIS T438S I263F V87F 19 
15 P411BM3-CIS T438S I263F A268T < 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MeO
Catalyst
0.3 % loading
TsN3
4 hours, RT MeO
NHTs
OH
21
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Table S2. Non-P450BM3 catalysts tested for activity in the above reaction for nitrene 
transfer to 4-methoxystyrene.  Myoglobin and cytochrome C were purchased as lyophilized 
powder from Sigma Aldrich.  CYP119 and P450RhF mutants were expressed and purified as 
described above.   
 
Entry Catalyst TTN 2 
1 Hemin < 1 
2 Hemin + BSA < 1 
3 Myoglobin < 1 
4 Cytochrome C < 1 
5 P450CYP119  C317S 7 
6 P450CYP119 T213A C317H < 1 
7 P450Rhf < 1 
8 P450Rhf T275A < 1  
 
 
Table S3. Mutations present in P450BM3 variants used in this work. 
 Enzyme Mutations relative to wild-type P450BM3 
P450BM3 none 
P450BM3-T268A T268A 
P411BM3 C400S 
P411BM3-T268A T268A, C400S 
P450BM3-CIS T438S V78A, F87V, P142S, T175I, A184V, S226R, 
H236Q, E252G, A290V, L353V, I366V, T438S, 
E442K 
P411BM3-CIS T438S P450BM3-CIS C400S, T438S 
P-I263F P411BM3-CIS T438S I263F 
P-I263F-A328V P411BM3-CIS T438S I263F A328V 
P-I263F-A328V-L437V P411BM3-CIS T438S I263F A328V L437V 
P411BM3-CIS A268T T438S P450BM3-CIS, A268T, C400S, T438S 
P411BM3 H2-A-10 P450BM3-CIS, L75A, L181A, C400S, 
P411BM3 H2-5-F10 P450BM3-CIS, L75A, I263A, C400S, L437A 
P411BM3 H2-4-D4 P450BM3-CIS, L75A, M177A, L181A, C400S, 
L437A, T438S  
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2. Synthetic Procedures  
 
Synthesis of substrates and standards. All olefins presented in main text Table 1 were 
obtained from commercial sources (Sigma Aldrich).  
 
 
 
 
 
N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-methylbenzenesulfonamide (2). 
Synthesized as previously reported.22 
 
1H NMR (400 MHz, CDCl3):  δ 7.72 (d, 2H, J = 8.1 Hz), 7.29 (d, 2H, J = 8.3 Hz), 7.19 
(d, 2H, J = 8.6 Hz), 6.84 (d, 2H, 8.6 Hz), 5.06 (dd, 1H, J = 8.1, 4.6 Hz), 4.73 (dd, 1H, J = 
8.7, 3.7 Hz), 3.78 (s, 3H), 3.20 (ddd, 1H, J = 13.3, 8.1, 3.7 Hz), 3.01 (ddd, 1H, J = 13.2, 
8.6, 4.6 Hz), 2.42 (s, 3H) 
 
13C NMR (101 MHz, CDCl3): δ 159.66, 143.69, 136.86, 133.00, 129.90, 127.26, 127.21, 
114.16, 72.50, 55.44, 50.30, 21.66 
 
HRMS (FAB+): calculated for C16H18NO4S ([M+H]+): 320.0956; found: 320.0950 
 
 
 
 
 
N-(p-Tolylsulfonyl)-2-(p-methylphenyl)aziridine (5).  Synthesized as previously 
reportedS2 with spectral data in agreement with literature reported values.23 
 
1H NMR (300 MHz, CDCl3): δ 7.86 (d, 2H,, J = 8.3 Hz), 7.32 (d, 2H), 7.10 (m, 4H), 3.74 
(dd, 1H, J = 7.2, 4.5Hz), 2.97 (d, 1H, J = 7.2 Hz), 2.43 (s, 3H), 2.38 (d, 1H, J = 4.5 Hz), 
2.31 (s, 3H).  
 
 
 
 
MeO
NHTs
OH
NTs
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N-(p-Tolylsulfonyl)-2-phenylaziridine (7). Synthesized as previously reported24 with 
spectral data in agreement with literature reported values.23 
 
1H NMR (300 MHz, CDCl3): δ 7.87 (d, 2H, J = 8.3 Hz) 7.19-7.36 (m, 7H), 3.77 (dd, 1H, J 
= 7.2, 4.5 Hz), 2.98 (d, 1H, J = 7.2 Hz), 2.43 (s, 3H), 2.39 (d, 1H, J = 4.5 Hz) 
 
 
 
 
 
N-(p-Tolylsulfonyl)-2-(p-methoxyphenyl)aziridine (S1). Synthesized as previously 
reportedS2 with spectral data in agreement with literature reported values.23 
 
1H NMR (500 MHz, CDCl3):  δ 7.87  (d, 2H, J = 8.3 Hz), 7.34 (d, 2H, J = 8.5 Hz), 7.14 (d, 
J = 8.7 Hz, 2H), 6.83 (d, J = 8.7, 2H), 3.78 (s, 3H), 3.75 (dd, 1H, J = 7.2, 4.5 Hz), 2.97 (d, 
1H, J = 7.2 Hz), 2.44 (s, 3H), 2.39 (d, 1H, J = 4.5 Hz 
 
 
 
N-(p-Tolylsulfonyl)-2-(p-chlorophenyl)aziridine (S2).   Synthesized as previously 
reportedS2 with spectral data in agreement with literature reported values.23 
 
1H NMR (300 MHz, CDCl3):   δ 7.86 (d, 2H, J = 8.3 Hz), 7.34 (d, 2H, J = 7.9 Hz), 7.26 (d, 
2H, J = 8.5 Hz), 7.15 (d, 2H, J = 8.5 Hz), 3.73 (dd, 1H, J = 7.2, 4.4 Hz), 2.98 (d, 1H, J 
= 7.2 Hz), 2.44 (s, 3H), 2.34 (d, 1H, J = 4.4 Hz) 
 
 
 
 
N-(p-Tolylsulfonyl)-2-(m-chlorophenyl)aziridine (S3).   Synthesized as previously 
reportedS2 with spectral data in agreement with literature reported values.25 
 
NTs
NTs
MeO
Cl
NTs
NTs
Cl
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1H NMR (400 MHz, CDCl3):   δ 7.87 (d, 2H, J = 8.3 Hz), 7.35 (d, 2H, J = 7.7 Hz), 7.19 
– 7.26 (m, 3H), 7.12 (dt, 1H, J = 6.8, 1.8 Hz), 3.73 (dd, 1H, J = 7.2, 4.3 Hz), 2.97 (d, 1H, J 
= 7.2 Hz), 2.44 (s, 3H), 2.35 (d, 1H, J = 4.4 Hz) 
 
 
 
 
N-(p-Tolylsulfonyl)-2-(m-methylphenyl)aziridine (S4).   Synthesized as previously 
reportedS2 with spectral data in agreement with literature reported values.26 
 
1H NMR (400 MHz, CDCl3): δ 7.87 (d, 2H, J = 8.3 Hz), 7.33 (d, 2H, J = 8.6 Hz), 7.01 – 
7.20 (m, 4H), 3.74 (dd, 1H, J = 7.2, 4.5 Hz), 2.96 (d, 1H, J = 7.2 Hz), 2.43 (s, 3H), 2.38 (d, 
1H, J = 4.5 Hz), 2.30 (s, 3H) 
   
 
 
 
 
N-(p-Tolylsulfonyl)-2-(2,4-dimethylphenyl)aziridine (S5).  Synthesized as previously 
reported.24 
 
1H NMR (400 MHz, CDCl3): δ 7.90 (d, 2H, J = 8.4 Hz), 7.34 (d, 2H, J = 8.5 Hz), 6.91 – 
7.00 (m, 3H), 3.84 (dd, 1H, J = 7.2, 4.6 Hz), 2.97 (d, 1H, J = 7.2 Hz), 2.44 (s, 3H), 2.35 (s, 
3H), 2.32 (d, 1H, J = 4.6 Hz), 2.28 (s, 3H) 
 
13C NMR (101 MHz, CDCl3): δ 144.72, 137.95, 136.72, 135.15, 130.89, 130.32, 129.84, 
128.11, 126.82, 125.98, 39.61, 35.07, 21.75, 21.11, 19.08 
 
HRMS (FAB+): calculated for C17H20NO2S ([M+H]+): 302.1215; found: 302.1210 
 
 
 
 
 
N-(p-Tolylsulfonyl)-2-(naphthalene-2-yl)aziridine (S6).   Synthesized as previously 
reported24 with spectral data in agreement with literature reported values.23 
 
NTs
NTs
NTs
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1H NMR (400 MHz, CDCl3): δ 7.90 (d, 2H, J = 8.3 Hz), 7.75 – 7.81 (m, 3H), 7.73 (s, 
1H), 7.45 – 7.49 (m, 2H), 7.33 (d, 2H, J = 8.3 Hz), 7.25 – 7.30 (m, 1H), 3.93 (dd, 1H, J = 
7.2, 4.4 Hz), 3.07 (d, 1H, J = 7.2 Hz), 2.50 (d, 1H, J = 4.5 Hz), 2.42 (s, 3H) 
 
 
 
 
N-(2-hydroxy-2-phenylpropyl)-4-methylbenzenesulfonamide (S7). Synthesized as 
previously reported.22 
 
1H NMR (400 MHz, CDCl3): δ 7.67 (d, 2H, J = 8.3 Hz), 7.24 – 7.38 (m, 7H), 4.59 (s, 
1H), 3.22 (dd, 1H, J = 12.8, 8.5 Hz), 3.12 (dd, 1H, J = 12.8, 4.8 Hz), 2.42 (s, 3H), 1.56 (s, 
3H)  
 
13C NMR (101 MHz, CDCl3): δ 144.87, 143.73, 136.73, 129.93, 128.75, 127.60, 127.19, 
124.93, 73.81, 53.99, 27.62, 21.68 
 
HRMS (FAB+): calculated for C16H20NO3S ([M+H]+): 306.1164; found: 306.1160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NHTs
OH
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3.  Characterization of Enzymatic Aziridination  
 
Figure S1. Demonstration of enzymatic synthesis and degradation of aziridine S1 in 
reaction conditions 
 
A.  HPLC 220 nm chromatogram of controls.  
 
Co-injection of 4-methoxystyrene (Sigma Aldrich) and synthetic standard S1, confirmed by 
NMR.  
 
 
 
 
 
Synthetic standard S1, confirmed by NMR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MeO
NTs
MeO
Co-injection
+
NTs
MeO
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B.  HPLC 220 nm chromatograms of P411-enzymatic reaction with 4-methoxystyrene 1 
and tosyl azide as substrates analyzed at different time points. Putative aziridine S1 and 
amido-alcohol 2 are marked with arrows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0	  
min
NTs
MeO
OH
NHTs
MeO
10	  
30	  
min
60	  
min
  
137 
C.  HPLC 220 nm chromatograms of synthetic standard S1 in reaction conditions 
without P411 catalyst at several time points. Putative aziridine S1 and amido-alcohol 2 are 
marked with arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NTs
MeO
OH
NHTs
MeO
0	  
min
10	  
min
30	  
60	  
  
138 
4.  Structural Analysis of Aziridination Catalysts 
 
Figure S2.  Representation of the P411BM3-CIS-I263F-T438S active site.  
P411BM3-CIS-I263F-T438S active site is modeled from a previously solved structure (PDB 
ID: 4WG2).7  Active site residues V87, F263, and A268 are shown as pink sticks, with the 
heme cofactor as green sticks.  
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Figure S3. Comparison of active site residues in P-I263F and P-I263F-A328V-
L437V 
A) P411BM3-CIS-T438S structure (PDB ID: 4H23) with I263 shown as van Der Waals 
spheres in gold, L437 and A328 shown in pink.  B) P-I263F structure (PDB ID: 4WG2) 
showing the active site and residues F263, A328, and L437 as in pink.  C) P-I263F 
structure with A328V and L437V mutations implemented in silico using Pymol shown as 
gray van Der Waals spheres.  
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5.  Assignment of Absolute Configuration.   
Absolute stereochemistry of enzyme-produced aziridine 7 was assigned by chiral HPLC 
analysis and optical rotation. In particular, absolute stereochemistry of 7 was previously 
assigned by chiral HPLC using Chiracel OJ column (isopropanol/n-hexane mobile phase), 
with (S)-7 the earlier eluting enantiomer.27 Analytically enantiopure 7 produced by P-
I263F-A328V-L437V was subjected to the same chiral HPLC conditions and observed to 
be the earlier eluting enantiomer (Figure S11), leading to an assignment of (S)-7. Further 
support for this assignment came from measuring optical rotation. The optical rotation 
values for enantiomers of 7 have been previously reported (R)-7 [αD25] -80.25 (c =0.8, 
CHCl3) and (S)-7 [αD20]  +26.7 (c =0.7, CHCl3).28 Optical rotation measurement of 
analytically enantiopure 7 produced by P-I263F-A328V-L437V gave [αD25] +80.2 (c =1.2, 
CHCl3), revealing it to be (S)-7.  Similarly, the optical rotation of P-I263F-A328V-L437V 
produced 5 (analytically enantiopure) was measured to be [αD25]  +106.1 (c =0.45, CHCl3). 
By analogy, the configuration of enzymatically preferred (+)-5 is assigned as (S)-5.    
 
                         
 
                      (-)-7            (+)-6 
 
 
 
                        
 
         (-)-5    (-)-4 
 
NTs NTs
NTs NTs
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Figure S12.  Assignment of absolute stereochemistry of enzymatically produced 
aziridine 7 by chiral HPLC (Chiracel OJ, 30% isopropanol : 70% n-hexane, 210 nm).  
 
Racemic synthetic aziridine 7, tR = 16.7 min and 21.0 min.  
 
 
 
 
 
P-I263F-A328V-L437V produced aziridine 7, tR = 16.8 min. 
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6.  Initial rates for aziridination and azide reduction.   
 
Table S4. Initial rates for each enzyme and product were determined as described in 
Chapter 3, with reaction conditions as described above (Materials and Methods, 2.5 mM 
tosyl azide, 7.5 mM styrene 4).  Rates of sulfonamide (7) formation were determined in the 
presence of styrene 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NTs
Me Me
Enzyme
TsN3
anaerobic +
SO2NH2
Me
4 7
Enzyme! TOF 4!
(min-1)!
TOF 7!
(min-1)!
TOF 4/!
TOF 7!
TTN 4! TTN 7! TTN 4/ 
TTN 4 + 7!
P411BM3-CIS T438S (“P”)! 0.36! 13.2! 0.027! 8! 320! 0.024!
P-I263F! 9.2! 28.1! 0.34! 139! 261! 0.34!
P-I263F-A328V! 9.6! 27.6! 0.35! nd! nd! nd!
P-I263F-A328V-L437V! 6.0! 14.2! 0.42! 168! 228! 0.42!
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